TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page1of66CLINICALSTUDYPROTOCOL
Arandomized,open label,singledose,four waycrossover,PhaseIstudytocomparethe
pharmacokineticsofferricmaltolcapsulesandoralsuspensionunderfastedandfedconditionsin
adulthealthyvolunteers
ProtocolNumber: ST1001104
TestDrug: FerricMaltol(ST10)
EudraCTNumber: 201800007934
StudyName: Phase 1 crossover study of the PK of ferric maltol capsules and
suspension
Sponsor: ShieldTX(UK)Limited,NorthernDesignCenter,BalticBusiness
Quarter,GatesheadQuays,NE83DFUnitedKingdom
Version/Date: Version2.0,15July2020
ConfidentialityStatement
The informationcontainedinthisdocumentisprovidedin confidence. Itisunderstoodthat
thisinformationwillnotbeused,disclosedorpublishedwithoutwrittenconsentofShieldTX
(UK)Limited.

ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page3of662 TABLEOFCONTENTS
1 PROTOCOLAPPROVALS..................................................................................................................2
2 TABLEOFCONTENTS.......................................................................................................................3
3 ABBREVIATIONINDEX.....................................................................................................................7
4 SYNOPSIS.........................................................................................................................................9
5 BACKGROUNDINFORMATION......................................................................................................20
5.1 OVERVIEWOFDISEASE.........................................................................................................20
5.2 CURRENTTREATMENTOFDISEASE......................................................................................21
5.3 OVERVIEWOFTESTPRODUCT..............................................................................................22
5.4 DOSESELECTIONANDRESULTSOFPREVIOUSCLINICALSTUDIES.......................................22
5.4.1 Phase3studiesinadults...............................................................................................23
5.4.2 PhaseIstudiesinadults................................................................................................24
5.4.3 PhaseIstudyinchildrenandadolescents....................................................................24
5.5 RATIONALEFORTHESTUDY..................................................................................................26
5.5.1 StudyPopulation...........................................................................................................26
5.5.2 StudyTreatmentDuration............................................................................................26
5.6 RISKBENEFITEVALUATION...................................................................................................27
6 STUDYOBJECTIVESANDENDPOINTS............................................................................................29
6.1 PRIMARYOBJECTIVE.............................................................................................................29
6.2 SECONDARYOBJECTIVES ......................................................................................................29
6.3 PRIMARYENDPOINTS............................................................................................................29
6.4 SECONDARYENDPOINTS.......................................................................................................29
6.5 EXPLORATORYENDPOINTS...................................................................................................30
7 INVESTIGATIONALPLAN...............................................................................................................31
7.1 STUDYOVERVIEW.................................................................................................................31
7.2 INVESTIGATIONALSITES........................................................................................................32
7.3 INCLUSIONANDEXCLUSIONCRITERIA.................................................................................32
7.3.1 InclusionCriteria...........................................................................................................32
7.3.2 Exclusioncriteria...........................................................................................................33
7.4 CONCOMITANTMEDICATION...............................................................................................34
7.4.1 NotPermitted...............................................................................................................34
7.4.2 Permitted......................................................................................................................35
7.4.3 PotentialMedicationInteractions................................................................................35
7.5 INDIVIDUALDISCONTINUATIONCRITERIA............................................................................35
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page4of667.6 STUDYTERMINATION...........................................................................................................36
8 TREATMENTOFSUBJECTS............................................................................................................37
8.1 INVESTIGATIONALMEDICINALPRODUCT(IMP)PRESENTATION.........................................37
8.2 COMPARATOR.......................................................................................................................38
8.3 TREATMENTASSIGNMENTANDBLINDING..........................................................................38
8.3.1 TREATMENTASSIGNMENTANDADMINISTRATION.....................................................38
8.3.2 WASHOUTPERIOD........................................................................................................40
8.3.3 FOLLOWUP...................................................................................................................40
8.4 PACKAGING...........................................................................................................................40
8.5 STORAGE...............................................................................................................................40
8.6 LABELLING.............................................................................................................................40
8.7 TREATMENTCOMPLIANCE....................................................................................................40
8.8 CONTINUATIONOF TREATMENT..........................................................................................41
9 ENROLMENTANDRANDOMIZATIONPROCEDURES.....................................................................42
9.1 SCREENING............................................................................................................................42
9.2 COVID19TESTINGANDIMPLICATIONSONTHETRIAL........................................................42
9.3 RANDOMIZATION..................................................................................................................42
9.4 REPLACEMENTPOLICY..........................................................................................................43
9.5 BLINDINGPROCEDURES........................................................................................................43
9.6 EMERGENCYUNBLINDING....................................................................................................43
10 STUDYPROCEDURES.....................................................................................................................44
10.1 DESIGNSCHEMATICS............................................................................................................44
10.2 SCHEDULEOFASSESSMENTS................................................................................................45
10.3 DEMOGRAPHICSANDMEDICALHISTORY.............................................................................49
10.4 PHYSICALEXAMINATION......................................................................................................49
10.5 CONCOMITANTMEDICATIONSANDPROCEDURES..............................................................49
10.6 VITALSIGNS...........................................................................................................................49
10.7 LABORATORYASSESSMENTS................................................................................................50
10.7.1 HematologyandClinicalChemistry..............................................................................50
10.7.2 Pharmacokinetics..........................................................................................................50
10.7.3 HepatitisB,CandHIVtest............................................................................................51
10.7.4 UrineDrugtest..............................................................................................................51
10.7.5 PregnancyTest..............................................................................................................51
10.7.6 BreathAlcoholContentTest.........................................................................................52
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page5of6610.7.7 COVID 19Testing..........................................................................................................52
10.7.8 ECG................................................................................................................................52
10.7.9 Overallbloodvolume....................................................................................................52
11 SAFETY...........................................................................................................................................53
11.1 DEFINITIONS..........................................................................................................................53
11.1.1 ADVERSEEVENT(AE) ....................................................................................................53
11.1.2 SERIOUSADVERSEEVENT(SAE)....................................................................................54
11.2 REPORTINGANDDOCUMENTATION....................................................................................55
11.2.1 ImmediateReporting....................................................................................................56
11.2.2 Non ImmediateReporting............................................................................................57
11.3 EVALUATION.........................................................................................................................57
11.3.1 Intensity........................................................................................................................57
11.3.2 Causality........................................................................................................................57
11.3.3 Outcome .......................................................................................................................58
11.4 RE EXPOSURE........................................................................................................................58
11.5 SAFETYENDPOINTS...............................................................................................................58
12 STATISTICALCONSIDERATIONS.....................................................................................................59
12.1 SAMPLESIZEANDPOWERCALCULATIONS...........................................................................59
12.2 STATISTICALMETHODS.........................................................................................................59
12.2.1 SensitivityAnalyses.......................................................................................................60
12.2.2 ImputationofMissingData ..........................................................................................60
12.3 DEFINITIONOFPOPULATIONS..............................................................................................60
12.3.1 RandomizedPopulation................................................................................................60
12.3.2 SafetyPopulation..........................................................................................................60
12.3.3 FullAnalysisSet.............................................................................................................60
13 ETHICALCONSIDERATIONS...........................................................................................................61
13.1 DECLARATIONOF HELSINKI...................................................................................................61
13.2 INSTITUTIONALREVIEWBOARD/INDEPENDENTETHICSCOMMITTEE...............................61
13.3 SUBJECTINFORMATIONANDINFORMEDCONSENT............................................................61
13.4 SUBJECTDATAPROTECTION.................................................................................................62
13.5 SUBJECTINSURANCE.............................................................................................................62
13.6 CONFLICTOFINTEREST.........................................................................................................62
13.7 REGISTRATIONOFSTUDYANDDISCLOSUREOFRESULTS....................................................62
14 STUDYMANAGEMENT..................................................................................................................63
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page6of6614.1 SOURCEDATA.......................................................................................................................63
14.2 QUALITYASSURANCE............................................................................................................63
14.3 MONITORING........................................................................................................................63
14.4 STUDYFUNDING...................................................................................................................64
14.5 CONTRACTRESEARCHORGANIZATION(CRO)......................................................................64
14.6 AMENDMENTSTOTHESTUDYPROTOCOL...........................................................................64
14.7 STUDYSTOPPINGRULES.......................................................................................................64
14.8 ENDOFSTUDY.......................................................................................................................64
14.9 RETENTIONOFRECORDS......................................................................................................65
14.10 SECURITYANDPUBLICATIONS..............................................................................................65
15 REFERENCES..................................................................................................................................66
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page7of663 ABBREVIATIONINDEX
AE AdverseEvent
ALT AlanineAminotransferase
ANCOVA AnalysisofCovariance
AST AspartateAminotransferase
AUC AreaUnderthePlasmaConcentrationCurve
AUC(0inf) AreaUnderthePlasmaConcentrationCurvefor0 infinity
AUClastAreaUnderthePlasmaConcentrationCurvefrom0uptothelast
measurableconcentration(non below)quantificationlimitafter
dosing
BID TwiceDaily
BUN BloodUreaNitrogen
BP Bloodpressure
C Celsius
CA CompetentAuthority
CD CrohnsDisease
CI ConfidenceInterval
CKD ChronicKidneyDisease
Cmax MaximumObservedConcentration
COVID19 CoronavirusDisease2019
CRA ClinicalResearchAssociate
CRF/eCRF CaseReportForm/electronicCaseReportForm
CRO ContractResearchOrganization
CS ClinicallySignificant
CSR ClinicalStudyReport
CV CoefficientVariation
ECG Electrocardiogram
eGFR EstimatedGlomerularFiltrationRate
FDA FoodandDrugAdministration
GCP GoodClinicalPractice
GGT GammaGlutamylTranspeptidase
GI Gastrointestinal
hr Hour
Hb Hemoglobin
HIV HumanImmunodeficiencyVirus
IBD InflammatoryBowelDisease
ICH InternationalConferenceonHarmonization
ID IronDeficiency
IDA IronDeficiencyAnemia
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page8of66IEC IndependentEthicsCommittee
IMP InvestigationalMedicalProduct
IRB InstitutionalReviewBoard
IRT InteractiveResponseTechnology
IUD IntrauterineContraceptiveDevices
IV Intravenous
MAA MarketingAuthorizationApplication
NCS NonClinicallySignificant
NTBI NonTransferrinBoundIron
OFP OralFerrousProduct
PHI ProtectedHealthInformation
PIP PediatricInvestigationalPlan
PK Pharmacokinetics
PSP PediatricStudyPlan
SAE SeriousAdverseEvent
SAP StatisticalAnalysisPlan
SARSCoV2RT
PCRSevereAcuteRespiratory Syndromeassociated CoronavirusReal
TimeReverse TranscriptasePolymerase ChainReaction
SD StandardDeviation
TEAE Treatment emergentAdverseevent
TESAE Treatment emergentSeriousAdverseevent
TIBC TotalIronBindingCapacity
TLAGThedelaybetweenthetimeofdosingandtimeofappearanceof
concentrationinthesamplingcompartment.
Tmax TimetoMaximumPlasmaConcentration
TNFa TumorNecrosisFactoralpha
TSAT TransferrinSaturation
T1/2 Apparentterminaleliminationhalf life
UC UlcerativeColitis
UIBC UnsaturatedIronBindingCapacity
WHO WorldHealthOrganization
yrs Years
zApparentterminaleliminationrateconstant,determinedbylinear
regressionoftheterminalpointsoftheln linearplasma
concentration timecurve.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page9of664 SYNOPSIS
Title Arandomized,open label,singledose,four waycrossover,Phase
Istudytocomparethepharmacokineticsofferricmaltolcapsules
and oral suspension under fasted and fed conditions in adult
healthyvolunteers
ProtocolNumber ST1001104
StudyName Phase1crossoverstudyofthePKofferricmaltolcapsulesand
suspension
TestDrug FerricMaltol(ST10)
Comparator NotApplicable
Phase PhaseI
Sites Approximately1 2sites
StudyRationale Theexistingscientificandclinicalexperiencewithferricmaltolin
thetreatmentofIDAinpatientswithinflammatoryboweldisease
(IBD) and chronic kidney disease (CKD) supports its further
investigation in the treatment of iron deficiency/IDA in children
andadolescents,inlinewiththePediatricInvestigationPlan(PIP)
for Ferric Maltol that has been reviewed and approved by the
European Medicines Agency (PIP reference: EMEA001195PIP
0111)andthePediatricStudyPlan(PSP)agreedwiththeUSFDA
(IND114832).
Ferric Maltol makes iron available in the gastrointestinal tract,
providing the iron in a biologically labile form for uptake across
duodenal mucosal cells and ultimately hematopoiesis and
storageonferritin.
Randomized Phase III studies (ST10 01301/302) have
demonstrated that Ferric Maltol over a 12 week period
effectively increases Hb by over 2 g/dL compared to baseline in
irondeficiencyanemiapatientswithinflammatoryboweldisease
(IBD). Ferric Maltol was also demonstrated to be well tolerated
(87% of subjects completing 12 weeks of study treatment) and
withasideeffectprofilecomparabletotheplacebogroup.These
data formed the basis of a Marketing Authorization Application
(MAA) submission and subsequent EU centralized marketing
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page10of66authorization. Ferric Maltol 30 mg capsules (Feraccru®) are
approvedforthetreatmentofIronDeficiencyinadultstakenBID.
A randomized Phase III study (ST10 01303) in 167 patients with
IDA in Chronic Kidney Disease (CKD) over 16 week double blind
phase and an open label 36 week treatment in 125 subjects
demonstrated positive safety, efficacy and tolerability. Changes
in TSAT, ferritin, and serum iron concentrations indicated an
improvement in all iron parameters in the ferric maltol group
compared to the placebo group and through the open label 36
week treatment period to Week 52. Overall, Ferric Maltol
resulted in clinically and statistically significant increase in Hb
comparedtoplacebo.
As part of the pediatric clinical development, a Phase I PK study
was performed to understand the kinetics of the absorption of
iron and absorption and the elimination of maltol in a pediatric
subject group in order to establish a safe and effective dose in
children and adolescents, aged 1017 years. All 3 doses of Ferric
maltolwerewell toleratedandhadafavorablesafetyprofileover
a10dayperiod.
A new oral suspension formulation of ferric maltol has been
developed to provide an age appropriate formulation for
pediatric subjects. This study is designed to compare the PK of
the new suspension, in adults, with the existing ferric maltol
capsule.
Objectives Primaryobjective:
To evaluate the pharmacokinetics(PK)of ironabsorption aftera
single30mgdoseofferricmaltoladministeredascapsuleororal
suspension in fasted and fed conditions, via primary parameters
CmaxandAUC last.
Secondaryobjectives:
To evaluate the pharmacokinetics (PK) after a single 30mg dose
of ferric maltol administered as a capsule or oral suspension
(fastedandfedconditions);throughmeasurementsoftransferrin
saturation (TSAT), baseline corrected serum iron, transferrin,
totalandunsaturatedironbinding capacity(TIBCandUIBC),and
plasmaofmaltolandmaltolglucuronide.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page11of66Toassessthesafetyandtolerabilityofferricmaltolafterasingle
dose of 30 mg administered as a capsule or oral suspension
(fastedandfedconditions);basedonvital signs, adverseevents,
concomitant medications and routine clinical laboratory safety
bloodtests.
Endpoints Primaryendpoints:
1. PK analysis of total serum iron concentration; C max, AUClastin
fastedandfedconditions
Secondaryendpoints:
1. PKanalysisoftotalserumironconcentration;AUC infinfasted
andfedconditions
2. PK analysis of baseline corrected serum iron concentration;
Cmax,AUClast,AUCinfinfastedandfedconditions
3. PK analysis of maltol and maltol glucuronide in plasma; C max,
AUClastinfastedandfedconditions
4. PK analysis of TSAT, TIBC, UIBC, transferrin; C max, AUClastin
fastedandfedconditions
5. TreatmentemergentAdverseEvents(AEs)
6. SeriousAdverseEvents(SAEs)
7. Treatment emergent Adverse Events leading to premature
discontinuationofstudydrug/PKassessments
8. Clinicallaboratorysafetybloodresults
9. Changesinvitalsigns
10. Concomitantmedications
Design Thestudywillcompriseofthefollowingstages:
- Screening: to determine subject eligibility for the study
(within14 days prior tothe planned first ferricmaltol dosing
periodDay1foreachsubject)
- Randomized, Crossover phase: A treatment period of 4 days
with at least 48 hrs washout period between each dose
administration.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page12of66DuringthecrossoverPKphase,subjectswillberandomizedin
a 1:1:1:1 ratio to receive one of the following treatment
sequences.8subjectswillberandomizedtoeachsequence:
SequenceA:
o Period1;single dose of 30mgferric maltol capsule in
afedcondition
o Period 2; single dose of 30 mg (5 ml) ferric maltol
suspensioninafedcondition
o Period3;single dose of 30mgferric maltol capsule in
afastedcondition
o Period 4; single dose of 30 mg (5 ml) ferric maltol
suspensioninafastedcondition
SequenceB:
o Period 1; single dose of 30 mg (5 ml) ferric maltol
suspensioninafastedcondition
o Period2;single dose of 30mgferric maltol capsule in
afedcondition
o Period 3; single dose of 30 mg (5 ml) ferric maltol
suspensioninafedcondition
o Period4;single dose of 30mgferric maltol capsule in
afastedcondition
SequenceC:
o Period1;single dose of 30mgferric maltol capsule in
afastedcondition
o Period 2; single dose of 30 mg (5 ml) ferric maltol
suspensioninafastedcondition
o Period3;single dose of 30mgferric maltol capsule in
afedcondition
o Period 4; single dose of 30 mg (5 ml) ferric maltol
suspensioninafedcondition
SequenceD:
o Period 1; single dose of 30 mg (5 ml) ferric maltol
suspensioninafedcondition
o Period2;single dose of 30mgferric maltol capsule in
afastedcondition
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page13of66o Period 3; single dose of 30 mg (5 ml) ferric maltol
suspensioninafastedcondition
o Period4;single dose of 30mgferric maltol capsule in
afedcondition
Prior to the first treatment period, subjects will arrive at the
Clinical Unit on Day 1 at least 13 hrs before dosing. After at
least 10 hours overnight fasting at the Clinical Unit subjects
will be randomized to one of the 4 treatment sequences. PK
sampleswillbecollectedpre doseandupto24hrspost dose
during each period (12 times including pre dose) for the
measurements of serum iron, TSAT, TIBC, UIBC, transferrin,
plasmamaltolandmaltolglucuronide.
There will be at least 48 hrs washout period between dose
administrations.Subjectswillfastatleast10hrspriortoeach
treatmentperioddosing.
Subjects will stay at the Clinical Unit during the 4 treatment
and 3 washout periods and will be discharged on Day 8
followingthelastPKsamplingtimepoint.
- Posttreatment safety follow up: Post study telephone
followup will be conducted 3 7 days following Period 4
treatment.During earlydiscontinuation a safetyfollow up at
the Clinical Unit will be performed 3 7 days after the last
studymedication.
NumberofSubjects The target recruitment number is 32 and up to an additional 4
mayberecruitedtoreplaceearlywithdrawingsubjects.
InclusionCriteria 1. Must voluntarily sign and date each Institutional Review
Board (IRB)approved informed consent form (ICF) prior
to the initiation of any screening or study specific
procedures.
2. Willingandabletocomplywithstudyrequirements.
3. Healthy adult subjects 18 to 55 years of age, inclusive at
thetimeofinformedconsent.
4. BodyMassIndex(BMI)of1832kg/m2inclusive
5. Female subjects of childbearing potential must not be
planning a pregnancy or be pregnant or lactating. All
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page14of66female subjects must have a negative result for the
pregnancy tests performed at screening and each
treatmentperiod.
6. Female subjects of childbearing potential (including
perimenopausal females who have had a menstrual
periodwithin1yearpriortoscreening)mustagreetouse
areliablemethodofcontraceptionuntilstudycompletion
and for at least 4 weeks following their final study visit.
Reliable contraception is defined as a method which
results in a low failure rate, i.e., less than 1% per year
when used consistently and correctly, such as hormonal
contraception(oral,implant,injection, ring,orpatch)and
intrauterine contraceptive devices (IUDs) at least 3
monthspriortoScreeningoravasectomizedpartner.
Note: Completeabstinencefromsexualintercourseisan
acceptableformofcontraceptivepractice.
7. Female subjects of non childbearing potential must be
either surgically sterile (hysterectomy, bilateral tubal
ligation, bilateral salpingectomy and/or bilateral
oophorectomy at least 26 weeks before the Screening
Visit) or post menopausal, defined as spontaneous
amenorrheaforatleast2years.
8. Malesubjectswithpartnersofchildbearingpotential
musthavehadsurgicalsterilization(vasectomy)atleast
26weekspriortoScreeningoruseamalebarrier
methodofcontraception(i.e.malecondomwith
spermicide)duringanysexualintercourse,fromStudy
Day1(beginningofconfinement)until3monthsafter
theFollow upVisit.
Note: Completeabstinencefromsexualintercourseisan
acceptableformofcontraceptivepractice.
9. Male subjects must agree to abstain from sperm
donationfrominitialstudydrugadministrationthrough3
months after administration of the last dose of study
drug.
ExclusionCriteria A subject who meets any of the following criteria is not eligible
forparticipationinthestudy.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page15of661. Known hypersensitivity or allergy to the active substance or
excipientsofFerricmaltoloralsuspensionorcapsules;
2. Presence or history of any significant cardiovascular,
gastrointestinal, hepatic, renal, pulmonary, hematologic,
endocrine, immunologic, dermatologic, neurological, or
psychiatricdisease,asdeterminedbytheInvestigator;
3. Presenceorhistoryofanyothercondition(includingsurgery)
known to interfere with the absorption, distribution,
metabolism,orexcretionofmedicines;
4. Recent (within 6 months of screening) history of drug or
alcoholabuse;
5. Positive screen results for drugs of abuse or alcohol at
screeningorStudyDay1;
6. Consumption of alcohol within 72 hrs prior to study drug
administration;
7. Positive test result for hepatitis B surface antigen (HBSaAg),
hepatitis C virus antibody (HCV Ab), or human
immunodeficiencyvirusantibody(HIVAb)atscreening;
8. Donation or loss of 550 mL or more blood volume (including
plasmapheresis) or receipt of a transfusions of any blood
product within 8 weeks prior to study drug administration
and14daysforplasmadonationunlessmedicallyinadvisable;
9. Use of any prescription medications or over the counter
medications, including herbal products from screening until
study completion, other than medication used for
contraception or for treatment of any emergent AE at the
discretionoftheInvestigator;
10. Hasreceivedwithin 28dayspriorto Screeningintramuscular
or intravenous (IV) injection or administration of depot iron
preparation;
11. Hasreceivedoralironsupplementationwithin7dayspriorto
Screening;
12. Hasconcomitantdiseasethatwouldsignificantlycompromise
iron absorption or absorbed iron utilization such as
swallowing disorders; gastric pH disturbances and/or
extensivesmallbowelresection;
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page16of6613. Scheduled or expected hospitalization and/or surgery during
thecourseofthestudy;
14. Diagnosed to be COVID 19 positive by polymerase chain
reactiontesting(SARS CoV2RTPCRpositive)ofarespiratory
specimen(preferablyanasopharyngealswab)onDay 2;
15. Participation in any other interventional clinical study within
28dayspriortoScreening;
16. Any other unspecified reason that, in the opinion of the
Investigator or the Sponsor makesthe subject unsuitable for
enrolment.
ConcomitantMedication NotPermitted:
 Treatmentwithotheroralironpreparations(prescriptionand
nonprescription) within 7 days prior to screening and
throughoutthestudyperiod;
 Treatment with parenteral iron preparations within 28 days
priortoscreeningandthroughoutthestudyperiod;
 Oralantibiotics,whichareprohibitedatscreeningandduring
thestudy;
 Blood transfusions within 12 weeks before screening and
duringthestudy;
 Erythropoiesis stimulating agents within 28 days before
screeningandduringthestudy;
 Multivitamins within 7 days prior to screening and
throughoutthestudyperiod;
 Otherprescriptionoroverthecountermedications,including
herbalproductsfromscreeninguntilstudycompletion.
Permitted:
 Oral contraceptives are allowed during the study, but the
subjectsmusthavebeenonastabledosefor3monthsbefore
randomisation;
 Ifnecessary,medicationusedfortreatmentofanyemergent
AEatthediscretionoftheInvestigatormaybegiven.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page17of66DiscontinuationCriteria Subjects may be discontinued prematurely during the study for
thefollowingreasons:
 Withdrawalofinformedconsent;
 Unwillingness or inability to comply with protocol
requirements;
 Pregnancy or not using a reliable method of birth control
(femalesubjectofchildbearingpotential);
 Useofprohibitedconcomitantmedications;
 SeriousadverseeventsthatarejudgedbytheInvestigatorto
berelatedtostudytreatment;
 Blood transfusions for any cause during the study treatment
period;
The reason for study drug discontinuation and the date of last
dose should be recorded in the eCRF. Subjectswho discontinue
treatment prematurely must return for safety follow up at the
Clinical Unit 37 days after last medication, unless informed
consent is withdrawn (and the subject does not agree to attend
thisfollowupvisit).
InvestigationalMedicinal
Product
Comparator
Packaging
AdministrationFerric maltol oral suspension: oral suspension containing 30 mg
elemental iron, in the form of 231.5mg ferric maltol, in 5 ml
suspension.
Ferric maltol capsules: gelatin capsules with 30mg elemental
iron,intheformof231.5mgferricmaltol.
Ferric maltol bottles for capsules and oral suspension will be
labelledforclinicaltrialsuse.
Ferricmaltolcapsuleandsuspensionfastedconditions:following
anovernightfastofatleast 10hours, the Investigatoror his/her
staffwill administertoeachsubjectasingle doseofferricmaltol
according to randomization sequence in a sitting position.
Capsules should be taken with 240 ml potable tap water.
Suspensioncanbetakenwith240mlpotabletapwaterifneeded.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page18of66Waterisallowedduringthe10hrsfastingbutnotallowedforone
hour beforeand two hoursafter drug administration (except for
drugadministration).Nofoodwillbeallowedforatleast4hours
postdose.
Ferricmaltolcapsuleandsuspensionfedconditions:followingan
overnightfastofatleast10hourssubjectswillreceiveatestmeal
30minutesprior to administrationof the drugproduct. Subjects
should finish their meal in 30 minutes or less; however, the
capsuleorsuspensionwillbeadministeredbytheInvestigatoror
his staff 30 minutes after start of the meal. Capsules should be
taken with 240 ml potable tap water. Suspension can be taken
with240mlpotabletapwaterifneeded.Nofoodwillbeallowed
foratleast4hourspost dose.Waterisallowedduringthe10hrs
fasting but not allowed for one hour before and two hoursafter
drugadministration(exceptfordrugadministration).
StatisticalMethods Samplesizecalculation
The sample size is based on the comparisons of each of the
primary PK parameters C maxand AUC lastfor total serum iron
betweentheformulationsforeachofthetwoconditions:fedand
fasted. Each comparison will be made via the ratio of the two
values of the parameter between the formulations. The 90%
confidenceinterval(CI)forthisratiowillbereported.
Thus,thereare4primaryendpoints:
Infedcondition
Cmax(suspension)/ Cmax(capsule)
AUClast(suspension)/ AUClast(capsule)
Infastedcondition
Cmax(suspension)/ Cmax(capsule)
AUClast(suspension)/ AUClast(capsule)
Data from a previous study (ST10 01101) were used to provide
estimates of the standard deviations (SDs) of the logs of the
withinsubjectratiosoftheparametersC maxandAUC last(between
formulations).AssumingtheSDisnogreaterthan0.38,and that
the true ratio is 1, 20 subjects would provide a probability of at
least80%ofeachindividualconfidenceintervallyingwithin(80%,
125%). Further assuming thatall the 4 ratiosto be reported are
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page19of66independent, 31 subjects would provide probability of at least
80%ofall4confidenceintervalslyingwithin(80%,125%).Asthe
SDisuncertain,32subjectswillberecruitedinthestudy.
StatisticalMethods
For each of total serum iron, baseline corrected serum iron,
maltol, maltol glucuronide, TSAT, TIBC, UBIC and transferrin,
concentration data will be listed for each individual subject, by
formulation and condition (fed / fasted). The data will be
summarized, for each of the four formulations/conditions, at
each time point by using the following descriptive statistics: n
(the number of subjects), arithmetic mean, standard deviation
(SD), geometric mean, coefficient of variation (CV), median,
minimum and maximum, and a 90% confidence interval (CI) for
themean.
Concentration time courses of each analyte will be graphically
displayed per subject. For each feeding condition, plots of the
geometric mean concentration and its 90% CI, versus time, by
formulation,willbeprovided,overlaid.
For serum iron, baseline corrected serum iron, maltol, maltol
glucuronide,TSAT,TIBC,UIBCandtransferrin,thePKparameters
(Cmax, Tmax, AUClast, AUCinf,z, t½) will be listed and summarized,
foreachofthe fourformulations/conditions, usingthefollowing
descriptive statistics: n, arithmetic mean, SD, geometric mean,
CV,median,minimumandmaximum.
For total serum iron and baseline corrected serum iron, the
withinsubject ratios between the two formulations, in each of
theconditions(fedandfasted)oftheparametersC max,AUClastand
AUCinfwill be calculated per subject. These ratios will be
summarizedbyn,geometricmeananda90%confidenceinterval
forthemean.
Safety data will be listed and summarized for each
formulation/condition.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page20of665 BACKGROUNDINFORMATION
5.1 OVERVIEWOFDISEASE
The gold standard for diagnosing IDA is an iron stain of the bone marrow aspirate. Because
bonemarrowaspirationistooinvasivetobeusedonaregularbasis,theacceptedandreliable
method of diagnosis is based on a combination of parameters, including hematological and
ironmetabolism indices.Typically, decreased serum concentrations of hemoglobin (Hb) and
iron, mean corpuscular volume, ferritin concentration and transferrin saturation are
accompanied by increased total iron binding capacity, transferrin concentration, red blood
cell distribution width and erythrocyte protoporphyrin in comparison to age appropriate
reference ranges. Additionally, hypochromasia (meant by an excess of 10% of hypochromic
cells)isnotedontheperipheralbloodsmear(Thayu&Mamula,2005;Mamula etal,2002).
However, diagnosing IDA in the setting of inflammatory disease (e.g. Inflammatory Bowel
Disease,IBD)maybe complicateddue toinflammation.Inthesecircumstances, manyofthe
laboratorymeasuresofironstatusmaybeunreliable,asinflammationinfluencesparameters
ofironmetabolism (Thayu&Mamula, 2005).For instance,the elevationintransferrin levels
typical of iron deficiency may not be found, as patients with low albumin tend also to have
lowtransferrinconcentrations.Similarly,serumiron,transferrinsaturation(TSAT),totaliron
binding capacity (TIBC) and zinc protoporphyrin levels are often difficult to interpret in the
presence of inflammation. Finally, circulating concentrations of the iron storage protein
ferritin, the most accessible and well known measure of stored iron and the most powerful
testforirondeficiency,canbenormalorevenincreasedinresponsetoinflammation,asitis
an acute phase reactant, even in the presence of severe iron deficiency. Therefore, this
parameter may not provide adequate information about the storage compartment in the
setting of inflammatory conditions such as IBD, making it a less reliable marker because it
addsconfusiontotheclinicalpicture.
Accordingly,ithasbeensuggestedthatspecificdiagnosticcriteriaforIDAneedtobeadapted
to the level of inflammation. Thus, in patients without biochemical (Creactive protein, etc.)
orclinical(diarrhea,endoscopicfindings, etc.)evidenceofinflammation,thecut offpointfor
defininga low level of serumferritinis <30 g/L; however, in the presence of inflammation,
the lower limit of this parameter consistent with normal iron stores should be increased up
to100g/L.
The soluble transferrin receptor, a cell surface glycoprotein, is a truncated fragment of the
membrane receptor whose levels are increased when the availability of bone marrow iron
storesforerythropoiesisarelow,asinIDA.Asthecirculatingconcentrationisnotaffectedby
anemia of chronic disease, increased concentration of soluble transferrin receptor and the
ratio of soluble transferrin receptor/log ferritin has been proposed for reliable differential
diagnosis of these overlapping conditions (Gasche et al, 2004). However, this assay is used
primarily as a secondary measure, because it is not yet widely available and published data
existonlyforpediatricIBD(Weiss&Gasche,2010).
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page21of66Other aids to the differentiation between IDA and anemia of chronic disease, essential in
order to provide the appropriate treatment, include quantification of reticulocyte
hemoglobin and the percentage of hypochromic red cells, which indicate the availability of
ironforerythroidprogenitors,aswellasdeterminationofhepcidininserum(Weiss&Gasche,
2010). While anemia of chronic disease is mostly normochromic and normocytic, IDA more
frequentlypresentsasmicrocyticandhypochromicanemia.
5.2 CURRENTTREATMENTOFDISEASE
There is a clear unmet medical need for an alternative oral treatment for anemic patients,
particularlythosewhoareintoleranttoferroussulfate,toavoidtheneedforIVirontherapy,
regardlessofthecauseoftheirondeficiency. Theproposednewpediatricoralsuspensionof
ferricmaltolisbeingdevelopedinthetreatmentofirondeficiency(withorwithoutanemia).
The first approach to correct iron deficiencies is related to diet and lifestyle. Mild iron
deficiency can be corrected by increasing the intake of iron rich food (particularly that
containing the better absorbed haem iron), and by increasing the absorption of iron by
avoiding concomitant intake of tea (for example) or by concomitant ingestion of vitamin C.
The ultimate goal of dietary changes or pharmacological treatment is the return of
hemoglobin concentrations to the age appropriate reference range. The duration of
treatmentshould be sufficient to normalize notonly the hemoglobin value but also the iron
stores. In the case of individuals with underlying diseases associated with IDA, the primary
diseasemustalsobeaddressed,ofcourse.
The mainstay of treatment of iron deficiency anemia is oral iron supplements. Ferrous
compounds (sulfate, fumarate and gluconate), which are available both in solid and liquid
forms, are the most common due to the extremely low bioavailabilityof conventional ferric
preparations. The usual adult dose is 180 mg of elemental iron/day in divided doses.
Therapeutic doses can range from 100 to 200 mg of elemental iron/day, depending on
severityofsymptoms,ferritinlevels,ageofthepatient,andgastrointestinalsideeffects.
Intramuscular iron compounds are not widely used due to the multiple side effects and the
existenceofintravenousagents.
Intravenous iron preparations are considered treatment options after the failure of oral
therapy or in specific cases in which iron stores and the degree of anemia warrant acute
therapy. TheysometimesbecomenecessaryinthecaseofactiveIBD(flare ups),forexample,
because chronic inflammation inhibits iron absorption in the duodenum because of the
combined actions of hepcidin and TNF (Weiss & Gasche, 2010). The major drawback
concerning intravenous iron is that tight physiological regulation of iron absorption is
bypassed,sothereisanimportantriskforpotentialironoverloadandassociatedtoxicity.
Blood transfusions are widely used as an immediate intervention for rapid correction of
severeor life threateninganemia. However,suchtransfusionsdo notcorrecttheunderlying
pathology and do not have a lasting effect. The decision on whether to administer blood
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page22of66should not, therefore, be based only on the hemoglobin level, but should also take clinical
symptomsandco morbidityintoaccount(Weiss&Gasche,2010).
5.3 OVERVIEWOFTESTPRODUCT
Toovercome the significant challengesof iron substitution withoral ferrousproducts(OFP),
ferric maltol, a chemically stable complex formed between ferric iron (Fe3+) and maltol (3
hydroxy2methyl4pyrone)wasdeveloped. FerricmaltolmakesironavailableintheGItract,
providing the iron in a biologically labile form for uptake onto transferrin and ferritin and
ultimately hematopoiesis and storage on ferritin. European Commission marketing
authorization wasgrantedfor Ferric Maltol in February 2016and US FDA NDA approval was
grantedon25July2019. Thecurrentlyapproveddoseis30mgtwicedaily(BID),takeninthe
morningandeveningonanemptystomach.
Unlike OFPs, which are often given with food in order to reduce side effects, Ferric Maltol
should, be given on an empty stomach to maximize bioavailability. Oral ferric iron chelated
with maltol can be administered with improved tolerability and the total dose exposure of
unabsorbedironwithintheGItractissignificantlyreduced.
Phase I studies (ST1001101 and ST10 01102) in adults confirm that following absorption,
maltol undergoes rapid and complete first pass metabolism, is bio transformed to maltol
glucuronide, and excreted in the urine. This is consistent with the known metabolism and
excretionofmaltolabsorbednaturallyfromthediet(WHO,1980;WHO,2006).
PhaseIstudy(ST10 01103)inchildrenandadolescents,aged10 17yearswasperformedto
study 3 different doses of ferric maltol (7.8 mg, 16.6 mg and 30 mg BID) over a 10 day
treatment period. All 3 doses were well tolerated and had a favorable safety profile in this
population.
A new oral suspension formulation of ferric maltol has been developed to provide an age
appropriateformulationforpediatricsubjects.
5.4 DOSESELECTIONANDRESULTSOFPREVIOUSCLINICALSTUDIES
FerricmaltolisnotabsorbedsystemicallyasanintactcomplexandtraditionalPKstudiesmay
notprovidetherelevantinformation(Barrand1991a,b).Therefore,amodelwasdeveloped
todeterminetheoptimaldose. Datafrom6previousstudiesofFerricMaltolinsubjectswith
IBD and IDA were used to estimate absorption rates in the study population. Using these
data, the model suggested that in a compliant adult population, 30 mg Ferric Maltol twice
dailywouldresultincorrectionofbaselineanemiainthemajorityofsubjects. Thishasbeen
confirmedbythePhase3studiesconductedtodate(seebelow).
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page23of665.4.1 Phase3studiesinadults
ST1001301/302study
APhase3studyhasbeencompletedinadultsubjectswithIDAandIBD,whoareintolerantof
oralironproductsorareunsuitablefortreatmentwiththem(ST10 01301andST10 01302;
Gasche, 2015; Schmidt, 2016), using a dose of 30 mg BID Ferric Maltol, or 60 mg elemental
iron total daily dose. 128 subjects were randomized to 12 weeks of blinded medication (30
mg BID Ferric Maltol or matched placebo capsule) followed by a 52 week open label
extensionperiod;duringwhichallavailablesubjectsreceivedFerricMaltolatthesamedose.
87% and 82% Ferric Maltol and placebo treated subjects, respectively, completed the 12
week double blind period. The difference between the treatment groups in mean Hb from
baseline to week 12 was 2.25 g/dL (ANCOVA p<0.0001). Hb increased to normal values at
week 12 in 65% of Ferric Maltol group and 10% of placebo subjects. When the placebo
subjects were transferred to Ferric Maltol treatment in the open label phase, there was a
sharp rise in Hb levels that mirrored the response in the Ferric Maltol group in the double
blind phase. There were further increases in Hb up to 48 weeks of treatment and no
indicationofanyreductioninefficacyoverthefull64 weektreatmentperiod.
ST1001303study
A double blind, randomized, placebo controlled study in 167 patients with Iron Deficiency
AnemiainChronicKidneyDiseasewasperformedina2:1randomization.Ferricmaltol30mg
capsules or matching placebo were administered bid for 16 weeks followed by open label
treatmentwithferricmaltol30mgcapsulesforuptoanadditional36weeks.
167patientswithIDAinChronicKidneyDisease (CKD)over 16 weekdoubleblindphaseand
anopenlabel 36 weektreatmentin125 subjectsdemonstratedpositive safety,efficacyand
tolerability. Changes in TSAT, ferritin, and serum iron concentrations indicated an
improvementinallironparametersintheferricmaltolgroupcomparedtotheplacebogroup
andthroughtheopen label36weektreatmentperiodtoWeek52.
Theefficacyparametersinsubjectsoriginallyintheplacebogroupmovingtotheferricmaltol
group during the open label 36week treatment period mirrored the changes seen in the
ferric maltolgroup patientsduring the double blind 16week treatment period. No clinically
significantaccumulationwasobservedforeitherplasmamaltolorplasmamaltolglucuronide.
TheresultsindicatedthatsubjectswitheGFR>30mL/min/1.73m2mayexperienceagreater
treatment effect. Indeed, this would be expected due to a likely lower erythropoietin
responsetoanemiainthesubjectswithmoresevererenalimpairment.
The most common system organ class of study drug related TEAEs during the doubleblind
andopen labelperiodwasGIdisorders. Onlythreesubjectsexperiencedstudydrug related
adverse events that led to discontinuation in the double blind phase and 5 subjects in the
openlabel phase. Changes in laboratory values were mainly consistent with the disease
progressionandallofthemwereconsideredasnotrelatedtostudydrug.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page24of66In general, ferric maltol was well tolerated with only minor differences in the safety profile
andoverallGIsideeffectscomparedtoplacebo.
5.4.2 PhaseIstudiesinadults
ST1001101study
Another open label, randomized Phase 1 study evaluated the pharmacokinetics of Ferric
Maltolanditseffectonironindicesinpatientswithirondeficiency(withorwithoutanemia).
24 subjects received Ferric Maltol 30, 60, or 90 mg BID over an 8 day period. PK and iron
uptake were assessed on Days 1 and 8. Ferric maltol showed predictable pharmacokinetics,
noaccumulationover7days,andimprovementsinironuptakeacrossthedoserange 3090
mgBID(Bokemeyer,2016).
ThePKdatafromthisstudyareconsistentwithpreviousdataindicatingthatmaltolisrapidly
glucuronidatedandrenallyexcretedafterST10dosing,whileironisindependentlyabsorbed.
Across the three dosing regimens investigated, exposure to maltol glucuronide increased
dose proportionally. Serum iron concentrations and TSAT values generally increased with
higherdoses,buttherewasnoclearrelationshipbetweentheseparametersandexposureto
maltolormaltolglucuronide.HigherNTBIlevelsweredetectedinthehigherdosingregimens.
Although the frequency of AEs was also higher with these dosing regimens, there is no
evidence that this was a consequence of elevated NTBI in these subjects. The reported AEs
wereconsistentwiththeestablishedsafetyprofileofST10.
ST1001102study
The study results showed that plasma and urinary PK parameters for maltol and maltol
glucuronidewereconsistentwithrapidmetabolismofmaltoltomaltolglucuronide,followed
by renal excretion. Total serum iron and TSAT increased after ST10 dosing, although there
wasnoclearrelationshipbetweeneitheroftheseparametersandexposureprofiletomaltol
ormaltolglucuronide.Therewasno evidence ofintactST10 inserum samples, asmeasured
indirectlybyNTBI,andtherewerenofindingsinthissub studythataffectedthesafetyprofile
ofST10.
ThelowserumNTBIvaluesareconsistentwiththesafetyprofileofST10.Unsurprisingly,given
theshortduration,therewerenosignificantsafetyfindingsinthissub study.
5.4.3 PhaseIstudyinchildrenandadolescents
ST1001103study
Anopenlabel,randomized,PhaseIstudywascompletedin37childrenandadolescents(aged
1017) after BID oral doses of 7.8 mg, 16.6 mg or 30 mg ferric maltol (ST10) over a 10 days
treatment period. Of the 37 subjects, there were 12 subjects in the 7.8 mg dose group, 13
subjects in the 16.6 mg dose group and 12 subjects in the 30 mg dose group. The primary
objective of the study was to assess the PK and iron uptake of these 3 doses, through
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page25of66measurement of serum iron, TSAT and plasma concentrations of maltol and maltol
glucuronide.
A onecompartment model with first order absorption withTLAG and first order elimination
kinetics describes plasma maltol glucuronide PK for ferric maltol according to the current
data.Theresultsshowedthatdoseproportionalityexistedoverthedoserangetestedinthis
study, although the predicted C maxof plasma maltol glucuronide on Day 10 slightly deviated
fromdoseproportionality.
Theexposureofiron(C maxandAUCs)wasestimatedusingtheNCAmethodwiththepredicted
iron concentrations and then dose proportionality was assessed using a power model. The
resultsshowedthat dose proportionalityfor iron did not exist over the dose rangetested in
this study. The Day 1 iron exposure parameters increased less than dose proportionally
probably because of the plateauing effectobserved between the 16.6 mg and 30 mg doses,
andtheDay10ironexposureparameterswerecomparableacrossthe3doses.
A direct effect linear model without intercept fit serum TSAT according to the current data.
ThepredictedresponseparametersofTSAT(C max,AUC Above_B,etc)wereestimatedusingthe
NCA method with the predicted TSAT. The response time profile had a similar pattern with
irontimeprofile.
Safety was assessed by evaluating TEAEs, SAEs, physical examinations, vital signs, 12 lead
ECGs,andlaboratoryparameters.Intotal,20(54.1%)subjectsexperiencedaTEAE:7(58.3%)
subjectsinthe7.8mgdosegroup,6(46.2%)subjectsinthe16.6mgdosegroup,and7(58.3%)
subjectsinthe30mgdosegroup.Treatment emergentadverseeventsweremostlymildand
no subjectshad a severe TEAE. One (7.7%) subject in the 16.6 mg dose group experienced a
TEAE of tonsillitis that led to withdrawal of study drug and study discontinuation; this event
wasconsideredbytheInvestigatortobemoderateinseverityandnotrelatedtostudydrug.
NosubjectsdiedorexperiencedanSAEduringthestudy.
Noclinicallymeaningfuldifferencesinmeanchangesfrombaseline inhematologyorclinical
chemistry parameters were noted between dose groups. Overall, individual shifts from
normal to abnormal in hematology and clinical chemistry laboratory parameters were
consideredasnotrelatedtostudydrugandnotclinicallysignificant.
No subjects had laboratory abnormalities that were considered as TEAEs, SAEs, or led to
withdrawalofstudydrugor studydiscontinuationTherewerenoclinicallymeaningfulmean
changesfrom baseline invitalsignsresultsor ECGparameters,andnosubjectshadclinically
significant abnormal ECG results. There was 1 abnormal, clinically significant physical
examination finding for the subject who had a TEAE of tonsillitis that led to withdrawal of
studydrugandstudydiscontinuation.
RefertotheInvestigatorBrochureforfurtherinformation.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page26of665.5 RATIONALEFORTHESTUDY
Clinical studies conducted to date, provide evidence for the effectiveness of Ferric Maltol in
adult patients with ID in IBD and CKD. Study ST10 01301/2 demonstrated that ferric maltol
is effective and well tolerated in patients who are intolerant of OFPs or are otherwise
unsuitableforOFPtreatment.
The existing scientific andclinical experience with ferricmaltol in the treatmentof ID/IDA in
adults supports its further investigation in the treatment of iron deficiency/IDA in children
and adolescents, in line with the Pediatric Investigation Plan (PIP) for Ferric Maltol that has
been reviewed and approved by the European Medicines Agency (PIP reference: EMEA
001195PIP0111)andtheFDA agreedinitialPediatricStudyPlan(PSP)(IND:114832).
By performing this Phase I crossover study, the exposure of the adult solid dose
pharmaceutical form (hard capsules) and the proposed pediatric oral suspension will be
comparedtoconfirmtherapeuticinterchangeability. Ferricmaltolcapsulesandtheneworal
ferricmaltolsuspensionwillalsobeevaluatedinfastedandfedconditions.
Becauseitisnotethical toperformnon therapeuticPhase 1studiesinchildren,thisstudyis
beingcompletedusingadultvolunteersubjects.
5.5.1 StudyPopulation
Thestudypopulationwillbehealthymaleandfemalesubjects,agedbetween18and55yrs,
inclusiveatthetimeofinformedconsent.
5.5.2 StudyTreatmentDuration
A treatment period of 4 days with at least 48 hours washout period between each dose
administration.
During the crossover PK phase, subjects will be randomized in a 1:1:1:1 ratio to receive one
ofthefollowingtreatmentsequences.8subjectswillberandomizedtoeachsequence:
SequenceA:
o Period1;singledoseof30mgferricmaltolcapsuleinafedcondition
o Period2;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period3;singledoseof30mgferricmaltolcapsuleinafastedcondition
o Period4;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
SequenceB:
o Period1;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period2;singledoseof30mgferricmaltolcapsuleinafedcondition
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page27of66o Period3;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period4;singledoseof30mgferricmaltolcapsuleinafastedcondition
SequenceC:
o Period1;singledoseof30mgferricmaltolcapsuleinafastedcondition
o Period2;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period3;singledoseof30mgferricmaltolcapsuleinafedcondition
o Period4;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
SequenceD:
o Period1;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period2;singledoseof30mgferricmaltolcapsuleinafastedcondition
o Period3;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period4;singledoseof30mgferricmaltolcapsuleinafedcondition
5.6 RISKBENEFITEVALUATION
The safety of Ferric Maltol in subjects with IDA and IBD has been established in a well
controlled Phase 3 clinical study with data having been collected over 12 weeks on 128
subjects in the double blind phase and for over 12 months in some subjects in open label
followup(Gasche,2015;Schmidt,2016). ThesafetyandtolerabilityofFerricMaltolinadults
withIDAinIBDstudywaspositive,withtheoverallAErateinFerricMaltolbeingcomparable
to the Placebo group over a 12 week period; 87% of Ferric Maltol subjects remained in the
study. ThisdataissupportedbysmallerpublishedclinicalstudiesusinghigherdosesofFerric
MaltolandbypreclinicalstudiestestingFerricMaltolinrodents(see Investigators Brochure).
The safety and tolerability study with Ferric Maltol in 167 subjects with CKD and IDA have
been positive with data collected over 16 weeks in a double blind phase. The TEAE was
comparable between the active (70.1%) and placebo group (75%) with the most commons
system organ class of GI disorders. Only three subjects experienced study drug related
adverse events that led to discontinuation. Overall, Ferric Maltol resulted in clinically and
statisticallysignificantincreaseinHbcomparedtoplacebo.
PreviousPhaseIPKstudy(ST10 01101)wasperformedtodescribethePKandironuptakein
24 iron deficient subjects in three different dosing regimens (30, 60, 90 mg BID). The most
commonlyreportedTEAEs(29.2%)wereGIdisorderswhichwereconsistentwiththemedical
history of the subjects, who were recruited from specialist GI clinics. A single SAE was
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page28of66reported which led to discontinuation of the study but was not considered to be related to
studytreatment.
The study population will recruit healthy subjects, male and female aged 18 and 55 yrs
inclusiveatthetimeofinformedconsent.Alleligiblesubjectswillentera4Periodtreatment
phasewith48hrswashoutbetween eachdose administration. Subjectswill eithertake a30
mgferricmaltolasacapsuleor5mloralsuspensionaccordingtotherandomizedsequences
oneachPeriodDay1.
PKassessmentswill takeplace for subjectsto assesstheeffect, thesafetyand tolerabilityof
ferricmaltoloralsuspensionandcapsule.StudyprocedurerisksarerelatedtoIVcannulation
and blood sampling, with fainting, minor bleeding and bruising. The individual volume of
blood collected throughout the study (screening and PK assessment days) will not exceed
335.5mL,whichissubstantiallybelowthevolumeofroutineblooddonation.
Pregnancytestingwillensurethatpregnantfemalesubjectsdonotenterthestudy,andthat
anysubjectswhobecomepregnantduringthestudyaredetected.
The information gathered from this Phase I study will be very important in establishing the
interchangeabilitybetweenferricmaltolcapsulesandoralsuspension.
The risktothe subject relatedto studyprocedureshasbeenassessedasvery low,therefore
theriskbenefitisconsideredacceptable.
Refertothe Investigators Brochureforfurtherdetailsonrisk/benefitassessment.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page29of666 STUDYOBJECTIVESANDENDPOINTS
6.1 PRIMARYOBJECTIVE
To evaluate the pharmacokinetics (PK) of iron absorption after a single 30 mg dose of
ferricmaltoladministeredascapsuleororalsuspension(fastedandfedconditions),via
primaryparametersC maxandAUC last.
6.2 SECONDARYOBJECTIVES
To evaluate the pharmacokinetics (PK) after a single 30 mg dose of ferric maltol
administered as a capsule or oral suspension (fasted and fed conditions); through
measurements of transferrin saturation (TSAT), baseline corrected serum iron,
transferrin,totalandunsaturatedironbindingcapacity(TIBCandUIBC),andplasmaof
maltolandmaltolglucuronide.
To assess the safety and tolerability after a single dose of 30 mg Ferric Maltol
administeredasacapsuleororalsuspension(fastedandfedconditions);basedonvital
signs, adverse events, concomitant medications and routine clinical laboratory safety
bloodtests.
6.3 PRIMARYENDPOINTS
1. PK analysis of total serum iron concentration; C max, AUC lastin fasted and fed
conditions
6.4 SECONDARYENDPOINTS
1. PKanalysisoftotalserumironconcentration;AUC infinfastedandfedconditions
2. PK analysis of baseline corrected serum iron concentration; C max, AUClast,AUCinfin
fastedandfedconditions
3. PK analysis of maltol and maltol glucuronide in plasma; C max, AUClastin fasted and
fedconditions
4. PKanalysisofTSAT,TIBC,UIBC,transferrin;C max,AUClastinfastedandfedconditions
5. Treatment emergentAdverseEvents(TEAEs)
6. SeriousAdverseEvents(SAEs)
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page30of667. Treatment emergentAdverseEventsleadingtoprematurediscontinuationofstudy
drug/PKassessments
8. Clinicallaboratorysafetybloodresults
9. Changesinvitalsigns
10. Concomitantmedications
6.5 EXPLORATORYENDPOINTS
NotApplicable
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page31of667 INVESTIGATIONALPLAN
7.1 STUDYOVERVIEW
Thisisa,PhaseI,randomized,open label,singledose,four waycrossoverstudy,tocompare
the pharmacokinetics of iron and maltol absorption from ferric maltol capsules and oral
suspensionunderfastedandfedconditionsinadulthealthyvolunteers
Thestudywillcompriseofthefollowingstages:
 Screening:upto14days
 Randomizedtreatment:
A treatment period of 4 days with at least 48 hrs washout period between dose
administration.
During the crossover PK phase, subjects will be randomized in a 1:1:1:1 ratio to receive one
ofthefollowingtreatmentsequences.8subjectswillberandomizedtoeachsequence:
SequenceA:
o Period1;singledoseof30mgferricmaltolcapsuleinafedcondition
o Period2;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period3;singledoseof30mgferricmaltolcapsuleinafastedcondition
o Period4;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
SequenceB:
o Period1;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period2;singledoseof30mgferricmaltolcapsuleinafedcondition
o Period3;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period4;singledoseof30mgferricmaltolcapsuleinafastedcondition
SequenceC:
o Period1;singledoseof30mgferricmaltolcapsuleinafastedcondition
o Period2;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period3;singledoseof30mgferricmaltolcapsuleinafedcondition
o Period4;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
SequenceD:
o Period1;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period2;singledoseof30mgferricmaltolcapsuleinafastedcondition
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page32of66o Period3;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period4;singledoseof30mgferricmaltolcapsuleinafedcondition
Priortothefirsttreatmentperiod,subjectswillarriveattheClinicalUnitonDay 1atleast
13hrsbeforedosing.Afteratleast10hoursovernightfastingattheClinicalUnitsubjects
willberandomizedtooneofthe4treatmentsequences.PKsampleswillbecollectedpre
dose and up to 24 hrs post dose during eachperiod (11 times) for the measurements of
serumiron,TSAT,TIBC,UIBC,transferrin,plasmamaltolandmaltolglucuronide.
OnDay1subjectswillreceivestandardizedmealsaswell.
Subjects will stay at the Clinical Unit during the 4 treatment and 3 washout periods and
willbedischargedon Day8followingthelastPKsamplingtimepoint.Therewillbeatleast
48hourswashoutperiodbetweendoseadministrations.
- Posttreatment safety follow up: Post study telephone follow up will be conducted 3 7
daysfollowingthePeriod4treatmentday.
During early discontinuation a safetyfollow up at the Clinical Unit will be performed 3 7
daysafterthelaststudymedication.
Refer to Section 10.1 for a schematic of the study design and Section 10.2 for a detailed
scheduleofassessments.
7.2 INVESTIGATIONALSITES
Approximately1 2sites
7.3 INCLUSIONANDEXCLUSIONCRITERIA
Nodeviationstotheinclusionorexclusioncriteriaarepermitted.
7.3.1 InclusionCriteria
Allofthefollowingcriteriamustbemetforasubjecttoparticipateinthestudy:
1. Must voluntarily sign and date each Institutional Review Board (IRB) approved
informed consent form (ICF) prior to the initiation of any screening or study specific
procedures.
2. Willingandabletocomplywithstudyrequirements.
3. Healthyadultsubjects18to55yearsofage,inclusiveatthetimeofinformedconsent.
4. BodyMassIndex(BMI)of18 32kg/m2inclusive
5. Female subjects of childbearing potential must not be planning a pregnancy or be
pregnant or lactating. All female subjects must have a negative result for the
pregnancytestsperformedatscreeningandeachtreatmentperiod.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page33of666. Female subjects of childbearing potential (including perimenopausal females who
have had a menstrual period within 1 year prior to screening) must agree to use a
reliable method of contraception until study completion and for at least 4 weeks
following their final study visit. Reliable contraception is defined as a method which
results in a low failure rate, i.e., less than 1% per year when used consistently and
correctly,suchashormonalcontraception(oral,implants,injection,ring,orpatch)and
intrauterine contraceptive devices (IUDs), at least 3 months prior to Screening, or a
vasectomizedpartner.
Note: complete abstinence from sexual intercourse is an acceptable form of
contraceptivepractice.
7. Female subjects of nonchildbearing potential must be either surgically sterile
(hysterectomy, bilateral, tubal ligation, bilateral salpingectomy, and/or bilateral
oophorectomy at least 26 weeks before the Screening Visit) or post menopausal,
definedasspontaneousamenorrheaforatleast2years
Male subjects with partners of childbearing potential must have had surgical
sterilization (vasectomy) at least 26 weeks prior to Screening or use a male barrier
method of contraception (i.e. male condom with spermicide) during any sexual
intercourse from Study Day 1 (beginning of confinement) until 3 months after the
FollowupVisit.
Note: Complete abstinence from sexual intercourse is an acceptable form of
contraceptivepractice.
8. Male subjects must agree to abstain from sperm donation from initial study drug
administrationthrough3monthsafteradministrationofthelastdoseofstudydrug.
7.3.2 Exclusioncriteria
Asubjectwhomeetsanyofthefollowingcriteriaisnoteligibleforparticipationinthestudy.
1. Known hypersensitivity or allergy to the active substance or excipients of Ferric maltol
oralsuspensionorcapsules;
2. Presence or history of any significant cardiovascular, gastrointestinal, hepatic, renal,
pulmonary, hematologic, endocrine, immunologic, dermatologic, neurological, or
psychiatricdisease,asdeterminedbytheInvestigator;
3. Presenceorhistoryofanyothercondition(includingsurgery)knowntointerferewiththe
absorption,distribution,metabolism,orexcretionofmedicines;
4. Recent(within6monthsofscreening)historyofdrugoralcoholabuse;
5. Positive screen results for drugs of abuse, alcohol at screening or Study Day1 of Period
1;
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page34of666. Consumptionofalcoholwithin72hrspriortostudydrugadministration;
7. Positive test result for hepatitis B surface antigen (HBSaAg), hepatitis C virus antibody
(HCVAb),orhumanimmunodeficiencyvirusantibody(HIVAb)atscreening;
8. Donationorlossof550mLormorebloodvolumeorreceiptofatransfusionsofanyblood
product within 8 weeks prior to study drug administration and 14 days for plasma
donationunlessmedicallyinadvisable;
9. Useofany overthe countermedications, includingherbalproductwithin7dayspriorto
Screening until study completion. Except for ordinary pain (e.g. headache), some
analgesics(mainlyparacetamol)andcontraceptionwhichhavenodrug interactionswith
thestudyproductsmaybegiven;
10. Hasreceivedwithin28dayspriortoScreeningintramuscularorintravenous(IV)injection
oradministrationofdepotironpreparation;
11. Hasreceivedoralironsupplementationwithin7dayspriortoScreening;
12. Has concomitant disease that would significantly compromise iron absorption or
absorbed iron utilization such as swallowing disorders, gastric pH disturbance and/or
extensivesmallbowelresection;
13. Scheduledorexpectedhospitalizationand/orsurgeryduringthecourseofthestudy;
14. DiagnosedtobeCOVID 19positivebypolymerasechainreactiontesting(SARS CoV2RT
PCRpositive)ofarespiratoryspecimen(preferablyanasopharyngealswab)onDay 2;
15. Participationinanyotherinterventionalclinicalstudywithin28dayspriortoScreening;
16. Anyotherunspecifiedreasonthat,intheopinionoftheInvestigatorortheSponsormakes
thesubjectunsuitableforenrolment.
7.4 CONCOMITANTMEDICATION
7.4.1 NotPermitted
 Treatmentwithotheroral ironpreparations(prescription andnon prescription)within7
dayspriortoscreeningandthroughoutthestudyperiod;
 Treatment with parenteral iron preparations within 28 days prior to screening and
throughoutthestudyperiod;
 Oralantibiotics,whichareprohibitedatscreeningandduringthestudy;
 Bloodtransfusionswithin12weeksbeforescreeningandduringthestudy;
 Erythropoiesisstimulatingagentswithin28daysbeforescreeningandduringthestudy;
 Multivitaminswithin7dayspriortoscreeningandthroughoutthestudyperiod;
 Other prescription or over the counter medications, including herbal products from
screeninguntilstudycompletion.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page35of667.4.2 Permitted
 Oral contraceptives are allowed during the study, but the subjects must have been on a
stabledosefor3monthsbeforerandomisation;
 If necessary, medication used for treatment of any emergent AE at the discretion of the
Investigatormaybegiven.
7.4.3 PotentialMedicationInteractions
Irondruginteractionsofclinicalsignificancehavebeenreportedtooccurwithalargenumber
of concomitant therapies. Concurrent ingestion of oral iron causes marked decrease in the
bioavailability of a number of drugs due to the formation of iron drug complexes (chelation
orbindingofironbytheseconddrug).Examplesofaffecteddrugsare:IViron,penicillamine,
bisphosphonates, ciprofloxacin, entacapone, levodopa, levofloxacin, levothyroxine
(thyroxine) moxifloxacin, mycophenolate, norfloxacin,ofloxacin,tetracyclines, calcium and
magnesiumsalts,dimercaprol,chloramphenicolandmethyldopa.
Tominimizethepotentialfordruginteractions,concomitantmedicationsshouldbetakenat
least 4 hrs after ferric maltol. The exact timing of any concomitant medication should be
recordedintheeCRF.
7.5 INDIVIDUALDISCONTINUATIONCRITERIA
Subjectshave theright towithdrawconsent withoutprejudiceatanytime duringthe study.
Ifasubjectwithdrawsconsent,theInvestigatorshouldmakeareasonableefforttodetermine
thecause.AllwithdrawnsubjectsshouldhaveaPost StudyVisitwithin3 7daysattheClinical
Unitafterthelastdoseofstudydrug(ifthesubjectagreesinthecaseofwithdrawnconsent).
Subjectsmaybediscontinuedprematurelyduringthestudyforthefollowingreasons:
 Withdrawalofinformedconsent
 Unwillingnessorinabilitytocomplywithprotocolrequirements
 Pregnancyornotusingareliable methodofbirthcontrol(female subjectofchildbearing
potential)
 Useofprohibitedconcomitantmedications
 Serious adverse events that are judged by the Investigator to be related to study
treatment
 Bloodtransfusionsforanycauseduringthestudytreatmentperiod
Thereasonforstudydrugdiscontinuationandthedateoflastdoseshouldberecordedinthe
eCRF. Subjectswhodiscontinuetreatmentprematurelymustreturnforthesafetyfollowup
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page36of66attheClinicalUnit3 7daysafterlastmedication,unlessinformedconsentiswithdrawn(and
thesubjectdonotagreetoattendthisvisitfollow upvisit).
7.6 STUDYTERMINATION
The Sponsor reserves the right to temporarily halt and/or terminate the study (or if
appropriate, individual treatment dose groups) at any time for safety, scientific or ethical
reasonsincluding,butnotlimitedto:
- Emergingsafetyconcernsfromthisstudy,otherongoingstudieswithFerricMaltol,or
new and relevant scientific information, which result in the risk benefit ratio for this
studybecomingunfavorable,inthe Sponsors opinion.
- Ifthetotalnumberofdropoutsissohighorthenumberofincludedsubjectsissolow
that completion of the trial will not realistically be expected within a reasonable
timeframe.
- If the Sponsor determines the study will no longer reveal new knowledge and
consequentlyisethicallynolongerjustifiable.
IncaseofanearlyterminationofthestudyortemporaryhaltbytheSponsor,theIECandCA
will be notified within 15 calendar days, including a detailed written explanation of the
reasonsforthetermination/halt.
In all circumstances connected with temporary halt and/or termination of the study, the
followingprincipleswillapply:
- All affected parties (such as the IEC, CA, Investigators, heads of study center/clinic
directors)mustbeinformedasapplicableaccordingtolocallaw.
- All study materialsandsupplies (except documentation thatshouldremain storedat
site)mustbereturnedtotheSponsor/designee.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page37of668 TREATMENTOFSUBJECTS
Healthymale andfemalesubjectscomplyingwiththeinclusioncriteriaanddo notmeet any
oftheexclusioncriteriawillberandomlyassignedto4treatmentsequence.8subjectswillbe
randomizedtoeachsequence:
SequenceA:
o Period1;singledoseof30mgferricmaltolcapsuleinafedcondition
o Period2;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period3;singledoseof30mgferricmaltolcapsuleinafastedcondition
o Period4;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
SequenceB:
o Period1;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period2;singledoseof30mgferricmaltolcapsuleinafedcondition
o Period3;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period4;singledoseof30mgferricmaltolcapsuleinafastedcondition
SequenceC:
o Period1;singledoseof30mgferricmaltolcapsuleinafastedcondition
o Period2;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period3;singledoseof30mgferricmaltolcapsuleinafedcondition
o Period4;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
SequenceD:
o Period1;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period2;singledoseof30mgferricmaltolcapsuleinafastedcondition
o Period3;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period4;singledoseof30mgferricmaltolcapsuleinafedcondition
8.1 INVESTIGATIONALMEDICINALPRODUCT(IMP)PRESENTATION
 5ml(6mg/mlelementaliron)ferricmaltoloralsuspension.
Afulllistofexcipientscanbefoundinthe Investigators Brochure.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page38of668.2 COMPARATOR
 30mgferricmaltolcapsule
Afulllistofexcipientscanbefoundinthe Investigators Brochure.
8.3 TREATMENTASSIGNMENTANDBLINDING
The randomization procedure (created using a computer generated random permutation
procedure) will randomize the subject to one of the 4 treatment sequences to either
Sequence A Sequence B, Sequence C or Sequence D. The site will dispense the appropriate
formulation of openlabel ferric maltol bottles at each scheduled PK day according to the
scheduleofassessments.
Thisisanopenlabelstudyandtreatmentassignmentisnotblinded.
8.3.1 TREATMENTASSIGNMENTANDADMINISTRATION
Ferricmaltolcapsuleandsuspensionfastedconditions:
Priortothefirsttreatmentperiod,subjectswillarriveattheClinicalUnitonDay 1atleast13
hrsbeforedosing. Eligibilitywill becheckedagainbeforerandomizationand subjectswill be
dosed after the 0 hrs baseline blood sample according to their randomized sequence.
Capsulesshouldbetakenwith240mlpotabletapwater,mustbeswallowedwholeandmust
not be chewed, divided or crushed.5 ml suspension will be measured out by using 2 x 3 ml
syringe, graduated up to 2.5 ml. Subject can take suspension with 240 ml potable tap water
ifneeded.
Ahandandmouthcheckwillbeperformedimmediatelyafterdrugadministrationtoensure
thatthestudydrughasbeenswallowed.
Waterisallowedduringthe10hrsfastingbutnotallowedfor1hrbeforeand2hrspost dose
(exceptfor drug administration).Nofood willalsobe allowed for atleast4hourspost dose.
Within 30 mins following the 4 hours post dose blood samples, subjects will receive a
standardizedmeal.
Blood samples will be taken at 11 additional times after dosing; post dose PK sample times
will be 15mins ±2min, 30mins ±2min, 45mins ±5min, 1hr ±5min, 1,5 hr ±5min, 2hrs ±5
min, 3hrs ±5min,4hrs ±5min.6hrs ±10min,10hrs ±15minand24hrs ±15min.
Standardmealswillbeprovidedtothesubjectsat4,8,12hrsafterdrugadministrationinthe
morning. Meals will be identical in each treatment period. Iron content and time of
consumptionofeachmealwillberecordedduringthehospitalizationintheeCRF.
Subjectswillhavethefollowingmealtimes:
- Lunchwillbeserved:approximately4hrspostdose
- Snackwillbeserved:approximately8hrspost dose
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page39of66- Dinnerwillbeserved:approximately12hrspost dose
Subjects will stay in the Clinical Unit throughout the study period. During the washout,
subjects will stay at the Clinical Unit and receive standard meals. Iron content of the meals
willbemeasuredandrecordedintheeCRF.
Ferricmaltolcapsuleandsuspensionfedconditions:
Priortothefirsttreatmentperiod,subjectswillarriveattheClinicalUnitonDay 1atleast13
hrs before dosing. Eligibility will be checked again before randomization. Subjects will then
have their baseline blood samples taken and receive a test meal 30 minutes prior to
administration of ferric maltol. Subjects should finish their meal in 30 minutes or less;
however, ferric maltol will be administered 30 minutes after start of the meal. Capsules
shouldbetakenwith240mlpotabletapwater.Suspensioncanbetakenwith240mlpotable
tapwaterifneeded.
Ahandandmouthcheckwillbeperformedimmediatelyafterdrugadministrationtoensure
thatthestudydrughasbeenswallowed.
Waterisallowedduringthe10hrsfastingbutnotallowedfor1hrbeforeand2hrspost dose
(exceptfor drug administration).Nofood willalsobe allowed for atleast4hourspost dose.
Within 30 mins following the 4 hours post dose blood samples, subjects will receive a
standardizedmeal.
Bloodsampleswillbetakenat11additionaltimesafterdosing;thepost dosePKsampletimes
will be 15mins ±2min, 30mins ±2min, 45mins ±5min, 1hr ±5min, 1,5 hr ±5min, 2hrs ±5
min, 3hrs ±5min,4hrs ±5min,6hr ±10min,10hrs ±15minand24hrs ±15min.
Standardmealswillbeprovidedtothesubjectsat4,8,12hrsafterdrugadministrationinthe
morning. Meals will be identical in each treatment period. Iron content and time of
consumptionofeachmealwillberecordedduringthehospitalization.
Subjectswillhavethefollowingmealtimes:
- Breakfastwillbeserved30minutespriortodrugadministration
- Lunchwillbeserved:approximately4hrspost dose
- Snackwillbeserved:approximately8hrspost dose
- Dinnerwillbeserved:approximately12hrspost dose
A test meal should consist of, 150, 250, and 500 600 calories protein, carbohydrate and fat
respectively.Anexamplemeal: 2eggsfriedin butter, 2stripsofbacon,2slicesoftoastwith
butter,4ounces(113g)ofhashbrown,potatoand8ounces(227ml)ofwater.Substitutions
inthistestmealcanbemade aslong asthemealprovidesasimilaramount ofcaloriesfrom
protein, carbohydrate, andfatand hascomparable mealvolume andviscosity.Ifthe mealis
differentfromtheabovemention,itshouldbedocumentedintheeCRF.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page40of66Subjects will stay in the Clinical Unit throughout the study period. During the washout,
subjects will stay at the Clinical Unit and receive standard meals. Iron content of the meals
willbemeasuredandrecordedintheeCRF.
8.3.2 WASHOUTPERIOD
Washoutperiodlastsfor atleast48hrsbetweendoseadministration.
8.3.3 FOLLOWUP
Poststudytelephonefollow upwillbeconducted3 7daysfollowingperiod4treatmentday.
DuringearlydiscontinuationasafetyfollowupattheClinicalUnitwillbeperformed3 7days
afterthelaststudymedication.
8.4 PACKAGING
Capsule: Ferric Maltol capsuleswill be supplied in a white polypropylene securitainer with a
tamperevidentstandardsecuritainercapofwhitemediumdensitypolyethylene.Eachbottle
will contain 56 capsules. Site staff will dispense 1 capsule for each subject according to the
randomizationsequencegroup.
Oral suspension: Ferric maltol oral suspension will be supplied in 150 ml amber glass bottle
withanambercoloredgraduatedsyringe.Sitestaffwilladministerorally5mloralsuspension
accordingtotherandomizationsequence.
8.5 STORAGE
Ferricmaltolcapsulesandsuspensionmustbestoredbelow25 °Candmustnotbefrozen. In
the event that the drug is exposed to temperatures greater than or equal to 25°C,the
CRA/Sponsorshouldbecontactedforreviewandfurtherinstruction.
8.6 LABELLING
All bottles will be identified by a unique Bottle ID number. Bottles will be clearly labelled as
ferric maltol with the the strength indicated. Labels of the IMP will contain information
accordingto21CFRSection312.6.
Individual supplies packaging and labelling will be checked by the Investigator/designee
beforethesubjecttakestheirdoseofstudymedicationatsiteoneachPKday.
8.7 TREATMENTCOMPLIANCE
Subjects will be instructed to take the study drug as according to their individual
randomizationsequence.
Ifthesubjectisnon adherent,adecisionwillbemadebythemedicalmonitorand/orSponsor
astowhetherthesubjectshouldbewithdrawnfromthestudytreatment.
ProtocolST10 01104,Version 2.0,15Jul2020
TMP1CLI002ClinicalStudyProtocolandAmendmentTemplate
Version2.0:25Jan2017/Effective10Feb2017 CONFIDENTIAL Page41of66The delivery of medication to the site, its use and return, as well as subject specific
compliance,willbereconciledanddocumentedusingaDrugAccountabilityForminorderto
monitor compliance with the medication schedule. All opened containers, together with
remaining contents, and unopened containers will be kept by the Investigator in a secure,
lockedareauntilreturntothedrugsupplierbythemonitorordestructionbythesiteifagreed
with the Sponsor/designee. The Investigator will use the IMP only within the framework of
thisclinicalstudyandinaccordancewiththecurrent,approvedstudyprotocol.
8.8 CONTINUATIONOFTREATMENT
The information gathered from this Phase I study will be very important in establishing the
interchangeabilitybetweenferricmaltolcapsulesandoralsuspension.OncethisPhaseIstudy
hasbeencompleted,theresultswillbesubmittedtotheFDApriortocommencingthePhase
III Pediatric study. No further provisions are made for access to the study treatment under
thisprotocol.
ProtocolST10 01104,Version2.0,15Jul2020
CONFIDENTIAL Page42of669 ENROLMENTANDRANDOMIZATIONPROCEDURES
FulldetailsofprocedureswillbeprovidedintheInvestigatorSiteFileandeCRFCompletion
Guidelines.
9.1 SCREENING
Subjectswill be evaluatedaccording totheinclusion andexclusioncriteria(Sections7.3.1
and 7.3.2). Subjects will be deemed eligible for randomization if all inclusion criteria and
no exclusion criteria are met. The Investigator is required to document all screened
candidates considered for inclusion in this study. If excluded prior to randomization, the
reasonsforexclusionwillbe documentedinthe subjects eCRF,medicalnotesandon the
studyscreeninglog.
Asubjectmayberetestedonceforscreeninglaboratorycriteriathatdonotmeetprotocol
in/exclusion criteria initially, so long as randomization occurs no more than 14 days from
theinitialScreeningvisitdate(ifeligiblebasedonretestresults).
9.2 COVID19TESTINGANDIMPLICATIONSONTHETRIAL
Alleffortswillbemadebytheunittoavoidscreeninganysubjectswhomighthaveaknown
exposure to SARS CoV2or any symptoms suggestive of any infection with it by following
the guidelines provided by the Centers for Disease Control and Prevention (CDC) for
evaluatingpatientsforCOVID19.
Allsubjectswhoremainqualifiedaftertheirscreeningvisitwillgetarespiratoryspecimen
(preferably a nasopharyngeal swab) on Day 2 which will be tested for SARS CoV02 RT.
Subjects diagnosed to be COVID 19 positive by the polymerase chain reaction testing will
notbeadmittedtotheunitandexcludedfromthetrial.
The inpatient portion of the admitted and randomized trial subjects will be conducted in
compliancewiththemostcurrentguidelinesforCOVID 19preventionatthattime.
Ifthere isan occurrence or suspicion (based uponsigns and symptoms) of new COVID 19
infection in a subject after randomization, the subject may be withdrawn from the trial
treatmentandprocedures.
All COVID 19 positive test results will be recorded as an adverse event in the eCRF. The
subjects with known positive results or suspected COVID 19 will be advised to follow up
with their primary care physician or call the local health board for taking the appropriate
nextstepsfordiagnosisandtreatmentofCOVID 19.
Every attempt will be made to follow up with the adverse events via phone call to the
subjecttillknownresolutionorstabilizationofthedisease.
9.3 RANDOMIZATION
Subjects will be assigned a unique 3 digit subject identification number at the Screening
visit.
ProtocolST10 01104,Version2.0,15Jul2020
CONFIDENTIAL Page43of66A final eligibility evaluation must be conducted by the Investigator/designee prior to
randomization, oncethe resultsofall Screening andDay 1 assessmentsare available.No
subject may begin treatment prior to being randomized. The randomization procedure
(createdusingacomputer generatedrandompermutationprocedure)willrandomizethe
subjecttooneofthe4treatmentsequences.
9.4 REPLACEMENTPOLICY
Discontinuationsafterrandomizationforanyreasonsmaybereplacedatthediscretionof
the Sponsor, in order to reach the agreed number of evaluable subjects for
pharmacokinetic endpoints. Up to a maximum of 4 subjects may be recruited to replace
earlydiscontinuation.
9.5 BLINDINGPROCEDURES
Notapplicableasthisisanopenlabelstudy.
9.6 EMERGENCYUNBLINDING
Notapplicableasthisisanopenlabelstudy.
ProtocolST10 01104,Version2.0,15Jul2020
CONFIDENTIAL Page44of6610 STUDYPROCEDURES
10.1 DESIGNSCHEMATICS
SubjectswillbehospitalizedfromPeriod1Day 1anddischargedPeriod4,followingthe24hrspost dosesampling.
Safety blood sampling will take place at Period 4 following the 24 hrs post dose sampling and 3 7 days post dose subjects will have a telephone safety
followup.Subjectswhodiscontinuedearlyanddidnotwithdrawntheirconsent,willneedtoattendasafetyfollow up37daysafterdrugdiscontinuation.

ProtocolST10 01104,Version2.0,15Jul2020
CONFIDENTIAL Page45of6610.2 SCHEDULEOFASSESSMENTS
PERIODS SCREENING PERIOD1 Washout PERIOD2 Washout PERIOD3 Washout PERIOD4 Discharge15FOLLOW UP13
StudyDay Screening1211 2 3 4 5 6 7 8 1014
Followup
InformedConsent X
Demographics X
MedicalHistory X
ConcomitantMedicationsand
Procedures14X X X X X X X X X X X
PhysicalExamination X X (X)
VitalSigns2 X X X X X X (X)
ECG16 X
PregnancyTest3 X X X (X)
BloodsamplingforHepatitis
B,CandHIV4X
Urinetestfordrugscreen5 X X
Alcoholbreathalyzer6 X X
Haematology,Clinical
ChemistryandIronmarkers
bloodsampling8X X (X)
SARSCoV2RTPCR17 X
EligibilityConfirmationand
Randomization7 X X
ProtocolST10 01104,Version2.0,15Jul2020
CONFIDENTIAL Page46of66PERIODS SCREENING PERIOD1 Washout PERIOD2 Washout PERIOD3 Washout PERIOD4 Discharge15FOLLOW UP13
StudyDay Screening1211 2 3 4 5 6 7 8 1014
Followup
DispenseStudyDrug10 X X X X
Hospitalisation X
Standardisedsupervised
meal11X X X X
Standardisedmeal X X X X X X X X
Supervisedmorningdosing
withferric maltol12X X X X
PKBloodSamplingforIron
markers,maltol/maltol
glucuronide9X X X X X X X X
AdverseEvents X X X X X X X X X X
Subjectdischargeof
hospitalisation15X
Telephonecontact X
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page47of661. Asubjectmay beretestedonceforscreening laboratorycriteriathatdonotmeetprotocolin/exclusioncriteria,solong
asrandomizationoccursnomorethan14daysfromtheinitialscreeningdate(ifeligiblebasedonretestresults).
2. VitalSigns systolic/diastolic bloodpressure,pulserateandbodytemperatureateachtreatmentday,tobetakenafter
subjecthasbeensittingforatleast5minutes
3. Pregnancy test for female subjects of childbearing potential. Serum pregnancy test at Screening and Urine pregnancy
testatDay 1andDay8forfemalesubjectsofchildbearingpotential.
4. All subjects will have blood test at screening toshow if they have beeninfectedwith HepatitisC or HIV, or if theyhave
everbeeninfectedwithHepatitisBandstillhaveHepatitisBinthesubject`ssystem.HIVtestingwillbea2 stepprocess.
If the first test is positive, the blood will be testedagain. Until the secondtest results are negative, subjects will notbe
abletoparticipateinthestudy.
5. Urinefordrugtest:5PanelMultiLineTesttodetectamphetamines,cocaine,THC,opiatesandPCP.
6. Breathtestwill beperformedatScreeningandatPeriod1Day 1tomeasurethe BreathAlcoholContent(BAC)ofeach
subject.
7. Eligibility central laboratory sampling/assessments must be completed at Screening and on Period 1 Day 1 before the
subjectisrandomized.
8. Hematology,ClinicalChemistryandscreeningIronmarkersbloodsampling
9. On all four PK study days, all subjects will have baseline PK blood samples collected immediately prior to Ferric Maltol
dosing (0 hr). Subjects will then have furtherPK blood samples collected at 11 additional times afterdosing; the post
dosePKsampletimeswillbe 15mins ±2min, 30mins ±2min, 45mins ±5min, 1hr ±5min, 1,5hr ±5min,2hrs ±5min,
3hrs±5min,4hrs ±5min,6hr ±10min,10hrs ±15minand24hrs ±15min. Foreachindividualsubject,thepost dose
PKblood samplingschedulewill be the sameon all fourPKdays. PK bloodsampleson the PKdays will be:serumiron,
total and unsaturated iron binding capacity (TIBC, UIBC), transferrin, transferrin saturation (TSAT), maltol and maltol
glucuronide.
10. Drugdispensing:subjectswillberandomizedtoeitherSequenceA,B,CorD
SequenceA:
o Period1;singledoseof30mgferricmaltolcapsuleinafedcondition
o Period2;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period3;singledoseof30mgferricmaltolcapsuleinafastedcondition
o Period4;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
SequenceB:
o Period1;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period2;singledoseof30mgferricmaltolcapsuleinafedcondition
o Period3;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period4;singledoseof30mgferricmaltolcapsuleinafastedcondition
SequenceC:
o Period1;singledoseof30mgferricmaltolcapsuleinafastedcondition
o Period2;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period3;singledoseof30mgferricmaltolcapsuleinafedcondition
o Period4;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
SequenceD:
o Period1;singledoseof30mg(5ml)ferricmaltolsuspensioninafedcondition
o Period2;singledoseof30mgferricmaltolcapsuleinafastedcondition
o Period3;singledoseof30mg(5ml)ferricmaltolsuspensioninafastedcondition
o Period4;singledoseof30mgferricmaltolcapsuleinafedcondition
11. A test meal should consist of, 150, 250, and 500 600 calories protein, carbohydrate and fat respectively. An example
meal:2eggsfriedinbutter,2stripsofbacon,2slicesoftoastwithbutter,4ounces(113g)ofhashbrown,potatoand8
ounces(227ml) of water. Substitutionsinthis testmealcan be madeas longas the mealprovidesasimilar amountof
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page48of66caloriesfromprotein,carbohydrate,andfatandhascomparablemealvolumeandviscosity.Ifthemealisdifferentfrom
theabovemention,itshouldbedocumentedintheeCRF.
Subjectswillhavetheirtestmealsupervisedbysitestaff.
12. Ferric maltol capsule and suspension fasted conditions: Prior to the first treatment period, subjects will arrive at the
ClinicalUniton Day 1atleast 13hrsbefore dosing.Eligibilitywillbe checkedagainbeforerandomizationandsubjects
will be dosed after the 0 hrs baseline blood sample according to their randomized sequence. Capsules should be taken
with240mlpotabletapwater, mustbe swallowed wholeandmustnotbe chewed,dividedorcrushed.Suspensioncan
be takenwith 240 ml potable tap water if needed. A handand mouth check will be performed immediately after drug
administration to ensure that the study drug has been swallowed. Water is allowed during the 10 hrs fasting but not
allowedfor1hrbefore and2hrspost dose(exceptfordrugadministration).Nofoodwillalsobeallowedfor at least 4
hours post dose. Within 30 mins following the 4 hours post dose blood samples, subjects will receive a standardized
meal.
Blood samples will be taken at 11 additional times afterdosing; postdose PK sample times will be 15 mins ±2min, 30
mins±2min,45mins ±5min,1hr ±5min,1,5hr ±5min,2hrs ±5min, 3hrs ±5min,4hrs ±5min.6hrs ±10min,10hrs
±15minand24hrs ±15min.
Standard meals will be provided to the subjects at 4, 8, 12 hrs after drug administration in the morning. Meals will be
identical in each treatment period. Iron content and time of consumption of each meal will be recorded during the
hospitalizationintheeCRF.
Subjectswillhavethefollowingmealtimes:
- Lunchwillbeserved:approximately4hrspostdose
- Snackwillbeserved:approximately8hrspostdose
- Dinnerwillbeserved:approximately12hrspostdose
Ferricmaltolcapsuleandsuspensionfedconditions:Priortothefirsttreatmentperiod,subjectswillarriveattheClinical
Unit on Day 1 at least 13 hrs before dosing. Eligibility will be checked again before randomization. Subjects will then
havetheirbaselinebloodsamplestakenandreceiveameal30minutespriortoadministrationofferricmaltol.Subjects
should finish their meal in 30 minutes or less; however, ferric maltol will be administered 30 minutes after start of the
meal.Capsulesshouldbetakenwith240mlpotabletapwater.Suspensioncanbetakenwith240mlpotabletapwater
if needed. A hand and mouth check will be performed immediately after drug administration to ensure that the study
drughasbeenswallowed.Waterisallowedduringthe10hrsfastingbutnotallowedfor1hrbeforeand2hrspost dose
(except for drug administration). No food will also be allowed for at least 4 hours post dose. Within 30 mins following
the4hourspost dosebloodsamples,subjectswillreceiveastandardizedmeal.
Bloodsamples will be takenat 11additional timesafterdosing; the post dosePK sample times will be 15mins ±2min,
30 mins±2min, 45 mins ±5min, 1 hr ±5min, 1,5 hr ±5min, 2 hrs ±5min, 3 hrs ±5min, 4 hrs ±5min, 6 hr ±10min, 10
hrs±15minand24hrs ±15min.
Standard meals will be provided to the subjects at 4 and 8 hrs after drug administration in the morning. Meals will be
identical in each treatment period. Iron content and time of consumption of each meal will be recorded during the
hospitalization.
A hand and mouth check will be performed immediately after drug administration to ensure that the study drug has
beenswallowed.
Subjectswillhavethefollowingmealtimes:
- Breakfastwillbeserved30minutespriortodrugadministration
- Lunchwillbeserved:approximately4hrspost dose
- Snackwillbeserved:approximately8hrspost dose
- Dinnerwillbeserved:approximately12hrspost dose
Subjects will receive standardised meal during the study periodand iron content will be measured and recorded in the
eCRF.
13. Poststudytelephonefollow upwillbeconducted3 7daysfollowingPeriod4treatmentday .  Subjectswhodiscontinue
from the study prematurely should have final assessments conducted per /Post study Safety Follow Up at the Clinical
Unit,unlessconsentiswithdrawn.
14. To minimize the potential for drug interactions, concomitant medications should be taken at least 4 hrs after ferric
maltol.TheexacttimingofanyconcomitantmedicationshouldberecordedintheeCRF.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page49of6615. Subject will be discharged from the Clinical Unit following the 24 hrs blood sampling in Period 4 (Day 8), providing the
Investigatorhasnoongoingsafetyconcerns
16. ECGmachinereportedECGparametersandoverallclinicalECGinterpretationwillberecordedintheeCRF. ECGtobe
obtainedafterthesubjecthasbeensupineforatleasta10 minuterest.
17. SARSCoV2RTPCRwillbeperformedonDay 2.Subjectswithonly negativeresultswillbeabletoadmittothe Clinical
UnitonDay 1.
10.3 DEMOGRAPHICSANDMEDICALHISTORY
The following will be documented at Screening and updated (if required) prior to
randomization: Date of Birth, race and ethnicity, gender, all current medical conditions, all
clinically significant medical history from the past 5 years including all malignancies,
sterilizations,hospitalizationsandsurgeries;themethodofcontraceptionforfemalesubjects
of childbearing potential, if applicable. Body weight (Kg), height (m) will be measured at the
Screeningvisitonly.
10.4 PHYSICALEXAMINATION
A brief physical examination is to be conducted to assess safety. The examination should
include an assessment of general appearance, skin, head, eyes, ears, nose and throat,
cardiovascular,respiratory,abdominal,gastrointestinalandmusculoskeletalsystems.
10.5 CONCOMITANTMEDICATIONSANDPROCEDURES
The following will be documented at Screening and updated (if required) prior to
randomization: all currentmedicationsatthetimeofScreeningorstoppedwithin3months
ofscreeningandanymedicalprocedureperformedwithin3monthspriortoScreening.
The following will be documented throughout the study: any medications initiated, stopped
or with dose and/or frequency changes throughout the study. Any medical procedure
performedthroughoutthestudy.
Medical procedures to be documented are any therapeutic intervention such as
surgery/biopsy,physicaltherapyordiagnosticassessment(e.g.bloodgasmeasurement).
Tominimizethepotentialfordruginteractions,concomitantmedicationsshouldbetakenat
least 4 hrs after ferric maltol. The exact timing of any concomitant medication and its iron
contentshouldberecordedintheeCRF.
10.6 VITALSIGNS
Body temperature (°C),blood pressure and pulse rate will be assessed at Screening for all
subjects on all four PK daysat pre dose. Blood pressure and pulse rate should be measured
afterthesubjecthasbeensittingforatleast5minutesatScreeningvisitandateachPKdays
predose.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page50of6610.7 LABORATORYASSESSMENTS
10.7.1  HematologyandClinicalChemistry
Routine clinical laboratorysafetybloods for hematology(3.0mL) and clinical chemistry/iron
markers (7.5 mL) evaluationswill be collectedat Screening to assess eligibility. Hematology
(3mL)andclinicalchemistry(5.0mL)willberepeatedatPeriod4;24hrspost dosesampling
or at the Follow up visit for early discontinued subjects. Additional testing may be required
ifanyabnormalvalueisreportedandthismustbefolloweduntilitisresolved.
All analyses will be conducted by a central laboratory. Procedures for the collection,
processing, storing, and transporting of samples to the laboratory will be fully described in
thestudy specificLaboratoryManual.
Investigatorswillreview,signanddatealllabresultsuponreceiptfromthecentrallaboratory.
If a value is flagged as outside of the normal range, the Investigator must document the
abnormality as clinically significant (CS) ornonclinically significant (NCS). Any lab
abnormality assessed as CSmust be recorded as an AE if not explained by a pre existing
condition(documentedinthemedicalhistory).
The signed paper copy of the laboratory report is retained at the investigational site. The
electronicdatatransferredfromthecentrallaboratorydatabasetotheclinicalstudydatabase
will be considered source data for the derivation of summary data and listings presented in
theclinicalstudyreport.
10.7.1.1  Hematologytestparameters
Red blood cell count, hemoglobin, hematocrit, white blood cell count (total and differential
(%andabsolute),absolutereticulocytecountandplateletcount.
10.7.1.2  ClinicalChemistryandScreeningIronMarkerstestparameters
Clinical Chemistry: ALT, AST, alkaline phosphatase, gamma glutamyl transpeptidase (GGT),
total bilirubin, creatinine, blood urea nitrogen (BUN), sodium, potassium, chloride, calcium,
totalcholesterol,uricacid,glucose,totalprotein,albumin,bicarbonate,LDH,CK,triglycerides
IronMarkers:serumiron,transferrin,transferrinsaturation(TSAT),totalandunsaturatediron
bindingcapacity(TIBC,UIBC).
10.7.2  Pharmacokinetics
BloodsamplesformaltolandmaltolglucuronideonPKdays
4mlvenousbloodsampleswillbecollectedinlithium heparintubesbyindwellingcannulaor
venipuncture at the required times on the PK assessment days relative to the time of ferric
maltolmorningdosing: pre dose then11 further timesbetween0.15to24hourspost dose
(10.2).
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page51of66Followingcollectionandmixing,bloodsampleswillbecentrifuged,andtheresultantplasma
samples separated and stored at 20°Cat the study site, prior to collection and onward
transfer to the central laboratory on dry ice for subsequent assay of maltol and maltol
glucuronideplasmaconcentrationsusingappropriatelyvalidatedbioanalyticalmethods. Full
detailsoftherequiredsamplecollection,processingandhandlinglogisticswillbespecifiedin
thestudyspecificLaboratoryManual. Sampleswillbedestroyedattheendofthestudy,once
allanalysesarecomplete.
BloodsamplesforironmarkersonPKdays
2.5 mL venous blood samples will be collected in serum separator tubes (SST) by indwelling
cannula or venipuncture at the following times on the PK assessment days, relative to the
timeofferricmaltoldosing: pre dosethen11furthertimesbetween0.15 24hourspost dose
(sametimesasbloodsamplesformaltol/maltolglucuronideforeachindividual,section10.2).
Following collection and mixing, blood samples will be centrifuged, and the resultant serum
samples separated and split into 1 primary (ambient) and 1 frozen ( 20°C)aliquots at each
timepoint. Ambient serumsampleswillbe shippedtothecentrallaboratoryforsubsequent
assay of serum iron, transferrin, transferrin saturation (TSAT), total and unsaturated iron
bindingcapacity(TIBC,UIBC).
Full details of the required sample collection, processing and handling logistics will be
specified in the study specific Laboratory Manual. Samples will be destroyed at the end of
thestudy,onceallanalysesarecomplete.
10.7.3  HepatitisB,CandHIVtest
All subjects will have blood test (5 ml) at screening to show if they have been infected with
HepatitisCorHIV,oriftheyhaveeverbeeninfectedwithHepatitisBandstillhaveHepatitis
B in the subject`s system. HIV testing will be a 2 step process. If the first test is positive, the
bloodwillbetestedagain.Untilthesecondtestresultsarenegative,subjectswillnotbeable
toparticipateinthestudy.
10.7.4  UrineDrugtest
A 5 panel Multi Line Test will also be conducted at Screening to detect amphetamines,
cocaine,THC,opiatesandPCP.
10.7.5  PregnancyTest
Females ofchildbearing potentialonly. A serum pregnancytest should be conducted at the
Screening visit to assess eligibility using the test kits provided by the central laboratory. A
urine pregnancy test will be conducted at Period 1, Day1 and Period 4 Day 8 following the
24hrspostdosebloodsampling.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page52of66Fulldetailsoftherequiredsamplecollectionandprocessingprocedureswillbedescribedin
thestudy specificLaboratoryManual.
10.7.6  BreathAlcoholContentTest
EachsubjectwillhaveabreathalcoholcontenttestatscreeningandPeriod1,Day 1.
10.7.7  COVID19Testing
COVID19 polymerase chain reaction testing (SARS CoV2 RTPCR) of a respiratory specimen
(preferablyanasopharyngealswab)willbeperformedonDay 2.
10.7.8  ECG
MachinereportedstandardECGwithoverallclinicalECGinterpretationwillberecordedatScreening
intheeCRF.
10.7.9  Overallbloodvolume
Theindividualvolumeofbloodcollectedthroughoutthestudy(Screening,PKassessmentand
SafetyFollowup)willbeapproximately335.5ml.
Numberofbloodsamples
Totalnumberofsamplesperperiod:12PKtimepoints,1pre doseand11post dose.
Volumeperbloodsample
Screening:15.5ml
TotalbloodvolumeperPKdayincluding24hrspost dose(Period1,Period2,Period3):78ml
Total blood volume per PK day including 24 hrs post dose (Period 4, including safety follow
upbloodsamples):86ml
Totalbloodvolumepersubject:335.5ml
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page53of6611 SAFETY
11.1 DEFINITIONS
11.1.1  ADVERSEEVENT(AE)
An AE is any untoward medical occurrence in a subject administered a pharmaceutical
product and does not necessarily have a causal relationship with this treatment. An AE can
therefore be any unfavorable or unintended sign or symptom, intercurrent illness, injury, or
anyconcomitantimpairmentofthe subjects health,temporallyassociatedwiththeuseofa
medicinalproduct,whetherornotconsideredrelatedtothemedicinalproduct.
A treatmentemergent AE is any AE temporally associated with the use of a study drug,
whetherornotconsideredrelatedtothestudydrug.
AEsinclude:
 Exacerbation of a chronic or intermittent preexisting condition/disease/symptoms
present at baseline that worsen during the study including either an increase in
frequencyand/orintensity.
 Diseaseormedicalconditiondetectedordiagnosedafterstudydrugadministration
eventhoughitmayhavebeenpresentpriortothestartofthestudy.
 EventsconsideredbytheInvestigatortoberelatedtostudy mandatedprocedures.
 Abnormal safety assessments, e.g. laboratory test abnormalities, physical exam
findings, ECG or vital sign measurements must be reportedas AEsif they represent
a clinically significant finding in the medical and scientific judgment of the
Investigator,symptomaticornot, whichwasnotpresentatbaselineor ifpresent at
baseline, worsened during the course of the study or led to dose reduction,
interruption or permanent discontinuation of study drug. However, if an abnormal
laboratory or other safetyrelated test result is associated with clinical signs or
symptoms, the signs or symptoms should be recorded as an AE. If signs and
symptomsarepartofadiagnosis,thenthediagnosisshouldberecordedasAE.
 Signs,symptomsofasuspecteddruginteraction.
 Signs, symptomsofasuspectedoverdoseofeitherthestudydrugoraconcomitant
medication(overdosepersewillnotbereportedasAE/SAE).
AEsdonotinclude:
 Medical or surgical procedure, e.g., surgery, appendectomy, endoscopy, tooth
extraction, transfusion (as these are treatments for an AE). However, the event
resultingintheprocedureistheAE(e.g.appendicitis,abdominalpain).
 Preexisting disease or medical condition documented at baseline that does not
worsen.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page54of66 Situations in which an adverse change did not occur, e.g., hospitalizations for
cosmeticelectivesurgeryorforsocialand/orconveniencereasons.
 Anticipated day today fluctuations or seasonal fluctuations (e.g.allergic rhinitis) of
preexistingdisease(s)orcondition(s)documentedatbaseline.
 Thedisease/disorderbeingstudied,ortheexpectedprogression,signsorsymptoms
(includinglaboratoryvalues)ofthedisease/disorderbeingstudied,unlessitismore
severethanexpectedforthe subjects condition.
 Overdose of either study drug or concomitant medication without any signs or
symptoms.
11.1.2  SERIOUSADVERSEEVENT(SAE)
An SAE is any untoward medical occurrence between the time of consent and the subjects
finalvisitthat:
 isfatal,
 islifethreatening,
 requiresinpatienthospitalizationorprolongationofexistinghospitalization,
 resultsinpersistentorsignificantdisability/incapacity,
 resultsinacongenitalanomaly/birthdefector
 isotherwisejudgedasmedicallysignificant(mayjeopardizethesubject).
Thefollowingguidelinesshouldbeused:
Lifethreatening: Refers to an event in which the subject was at risk of death at the time of
the event; it does not refer to an event which hypothetically might have caused death if it
weremoresevere.
Inpatient hospitalization: Subject has to stay in hospital at least overnight. The following
reasonsforhospitalizationsarenotconsideredAEs,andthereforenotSAEs:
 Hospitalizations for cosmetic elective surgery, social and/or convenience reasons.
Standard monitoring of a pre existing disease or medical condition that did not
worsen, e.g.,hospitalizationforcoronaryangiographyinasubject withstable angina
pectoris.
 Electivetreatmentofapre existingdiseaseormedicalconditionthatdidnotworsen,
e.g., hospitalization for chemotherapy for cancer, elective hip replacement for
arthritis,veinstrippingforpreventiveand/orcosmeticpurpose.
Prolongation of hospitalization: Complications that occur during hospitalization are AEs.
However,ifacomplicationprolongshospitalizationorwouldhaverequiredhospitalizationor
fulfils any other serious criteria, that complication is considered an SAE. In any case,
admissiontoan intensivecare unitisconsidered a prolongationof hospitalization. Whenin
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page55of66doubt as to whether prolongation ofhospitalization was necessary, the AE should be
consideredserious.
Significant disability: The term significant disability means that there is a substantial
disruptionofa personsabilitytoconductnormallifefunctions. Thisdefinitionisnotintended
to include experiences of relatively minor medical significance such as uncomplicated
headache, nausea, vomiting, accidental trauma (e.g. sprained ankle) or uncomplicated
chronicdiseaseswhichmayinterfereorpreventeverydaylifefunctionsbutdonotconstitute
asubstantialdisruption.
Medically significant: Medical and scientific judgment should be exercised in deciding
whetherothersituationsshouldbeconsideredserioussuchasimportantmedicaleventsthat
mightnotbeimmediatelylife threateningorresultindeathorhospitalizationbutmight/may
jeopardize the subject or might/may require intervention to prevent one of the other
outcomes listed in the definition above. Examples of such events are invasive or malignant
cancers, intensive treatment in an emergency room or at home for allergic bronchospasm,
blooddyscrasiasor convulsionsthatdonotresultinhospitalization, or developmentofdrug
dependencyordrugabuse.
SAE related to studymandated procedures: Such SAEs are defined as SAEs that appear to
have a reasonable possibility of causal relationship (i.e., a relationship cannot be ruled out)
to study mandated procedures (excluding administration of study drug) such as
discontinuation of subject'sprevious treatment during a washoutperiod, or complication of
a mandatedinvasive procedure (e.g., blood sampling, heartcatheterization), or car accident
onthewaytothehospitalforastudyvisit,etc.
11.2 REPORTINGANDDOCUMENTATION
AEsshouldbedocumentedintermsofamedicaldiagnosis. Whenthisisnotpossible,theAE
should be documented in terms of signs and/or symptoms observed by the Investigator or
reportedbythesubjectateachstudyvisit.
Any preexisting conditions or signs and/or symptoms present in a subject prior to the start
ofthestudyshouldberecordedontheMedicalHistoryCRF.
All SAEs that occur after informed consent is obtained through study completion or
prematurediscontinuationmustbereportedontheSAEformintheCRFandreportedwithin
24hourstotheSponsor. AllAEsoccurringfromthetimeofthefirstdoseofstudytreatment
throughstudycompletionorprematurediscontinuationmustbereportedontheAEformin
theCRF.ForAEsrelatedtoCOVID 19testing,seesection9.2.
AnySAEthatoccursduringtheclinicalstudyorwithintwoweeksofreceivingthelastdoseof
studydrug,whetherornotrelatedtothestudydrug,mustbereportedtotheSponsor.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page56of66Deaths or congenital abnormalities if brought to the attention of the Investigator AT ANY
TIMEaftercessationofstudydrugANDconsideredbytheInvestigatortobepossiblyrelated
tostudydrug,shouldbereportedtotheSponsor.
AteachvisitAEswill besolicited.Thenatureofeacheventshouldbeestablished. Detailsof
changes to study drug dosing or any subsequent treatment should be recorded on the
appropriatepagesoftheCRF.
AEs already documented in the CRF (i.e., at a previous assessment) and designated as
'ongoing'shouldbereviewedatsubsequentvisitsasnecessary. Uponresolution,thedateof
resolutionshouldberecordedintheCRF. IfanAEincreasesinfrequencyorseverityduringa
study period, a new record of the event should be started. If the AE lessens in intensity, no
changeintheintensityisrequiredasonlytheworstintensitymustbereported.
All AEs and SAEs, including those that are ongoing at the end of the study or at premature
discontinuation, will be followed up until resolution or stabilization or until the event is
otherwiseexplained.
11.2.1  ImmediateReporting
ThefollowingAEsmustbereportedwithin24hourstotheSponsorordesignee:
 SAEs
 Pregnancy(notconsideredasanAE,butmustbereportedimmediately)
For immediate reporting, the Investigator must fill out the SAE form (also for pregnancies)
andsendtotheSponsorwithin24hoursafterawareness.
SAFETYCONTACTDETAILS
PrimevigilanceLimitedhasbeencontractedbytheSponsorforsafetyreporting
EmailSAEreportsto shieldpv@primevigilance.com orfaxto+448007816187
ContactdetailsforsafetyquestionswillbeprovidedintheInvestigatorSiteFile
Ifthesite obtainsrelevantfollow upinformation,thisinformationneedsto beforwardedto
the Sponsor within 24 hrs of awareness using a new SAE form and the updated AE form if
appropriate.
Other documents must be submitted upon request. All documents must be blinded with
respect to the subjects personal identification to meet data protection requirements, e.g.,
onthedischargesummarythisdatamustbeblinded,andthesubjectnumberadded.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page57of66As soon as the Sponsor is informed about an SAE, an evaluation and potential reporting to
central IRBs/IECs, Competent Authorities (CA) and other concerned parties will occur as
required.TheInvestigatorwillberesponsibleforreportingtoanylocalIRB/IECasrequired.
11.2.2  NonImmediateReporting
AEsthatdonotqualifyforimmediatereportingwillbedocumentedintheeCRFandreported
intheClinicalStudyReport(CSR).
11.3 EVALUATION
AEsandthecorrespondingentriesintheeCRFwillbereviewedbytheInvestigatororqualified
member of the study staff. Adverse events, toxicities and medical surgery/history will be
categorized by primary system organ class (SOC) and preferred term using the MedDRA
dictionary.Toxicitieswillalsobegradedasmild,moderateorsevere.
11.3.1  Intensity
TheintensitywillberatedbytheInvestigatoras mild,moderate orsevere:
Mild:Symptomsbarelynoticeabletothesubjectordoesnotmakethesubjectuncomfortable;
doesnotinfluenceperformanceorfunctioning.
Moderate: Symptoms of a sufficient severity to make the subject uncomfortable;
performanceofdailyactivityisinfluenced;subjectisabletocontinueinstudy.
Severe: Symptoms cause significant discomfort; incapacitation or significant impact on the
subjects dailylife;maycausecessationofstudytreatment.
Amild,moderateorsevereAEmayormaynotbeserious. Thesetermsareusedtodescribe
the intensity of a specific event (as in mild, moderate, or severe myocardial infarction).
However, a severe event may be of relatively minor medical significance (such as severe
headache) and is not necessarily serious. For example, nausea lasting several hoursmay be
rated as severe, but may not meet the definition of seriousness. Fever of 39 °Cthat is not
consideredseveremaybecomeseriousifitprolongshospitalization.
11.3.2  Causality
The followingshouldbe consideredwhenevaluatingthe relationshipofAEsand SAEstothe
studytreatment:
Not related: There is not a possibility that the event has been caused by the product under
investigation.Considerationshouldbegiventofactors,includingbutnotlimitedto,alackof
reasonable temporal relationship between administration of the drug and the event, the
presence ofa biologicallyimplausible relationshipbetweenthe product and the AE (e.g.the
event occurred before administration of drug), or the presence of a more likely alternative
explanationfortheAE.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page58of66Related: There is a possibility that the event may have been caused by the product under
investigation.Considerationshouldbegiventofactors,includingbutnotlimitedtoapositive
rechallenge, a reasonable temporal sequence between administration of the drug and the
event, a known response pattern of the suspected drug, improvement following
discontinuationordosereduction,abiologicallyplausiblerelationshipbetweenthedrugand
theAEoralackofanalternativeexplanationfortheAE.
11.3.3  Outcome
TheoutcomeofeachAEhastobeassessedasfollows:
 Fatal: TheAEresultedindeath (Death isrecordedasanoutcome,notastheAE)
 Ongoing/Notresolved:TheAEhasnotresolved
 Recoveredwithsequelae: ResolutionoftheAEhasoccurred,butthesubjectretains
somesequelae
 Recovered:TheAEfullyresolvedwithnoobservableresidualeffects
 Unknown: The outcome of the AE is not known as the subject did not return for
followupandattemptstolocatethesubjectand/ortoobtainfollow upinformation
wereunsuccessful(losttofollow up).
11.4 REEXPOSURE
If an AE requires discontinuation of IMP and is judged to be treatment related by the
Investigatoror by the Sponsor, re exposure isnot allowed. Ifan AE requiresdose reduction
ordiscontinuationofIMPandisjudgedbytheInvestigatororbytheSponsortobeunrelated
to investigational products, the decision to re introduce the medication or to increase the
doseofthemedicationrequirespriorapprovaloftheSponsorordesignee.
11.5 SAFETYENDPOINTS
During the study, safety endpoints will be treatment emergent AEs and SAEs, including
clinically significant changes from baseline in vital signs, physical examination and routine
clinicallaboratoryabnormalities.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page59of6612 STATISTICALCONSIDERATIONS
12.1 SAMPLESIZEANDPOWERCALCULATIONS
The sample size isbased onthecomparisonsofeachoftheprimaryPK parametersC maxand
AUClastfortotalserumironbetweentheformulations,withineachofthetwoconditions:fed
and fasted. Each comparison will be made via the ratio of the two values of the parameter
betweentheformulations. The90%confidenceinterval(CI)forthisratiowillbereported.
For each of the two comparisons (suspension vs capsule (fed condition); suspension vs
capsule (fasted condition))the CIsfor twoparameterratios(C maxand AUC last)for serumiron
will be calculated, making a total of 4 CIs. If these ratios were all independent, and the
probabilityofbeingwithin(80%,125%)was80%foreach,thentheprobabilitythatall4would
fall within the required limits would be (80%)4= 41%. With individual probabilities of 90%,
the combined probability would be 66%. However, if the ratios were positively correlated,
thecombinedprobabilitieswouldbehigher.
Data from a previous study (ST1001101) were used to provide estimates of the standard
deviations(SDs)ofthelogsofthewithin subjectratiosoftheparametersC maxandAUC last,for
bothtotalserumironandTSAT.AssumingtheSDisnogreaterthan0.38,ifthetrueratiois1,
31subjectswouldprovideaprobabilityofatleast80%ofall4CIslyingwithin(80%,125%).
Theaimofthestudyistodemonstratethatthe4CIsforserumironareallwithin(80%,125%).
As the SD, and the degree of correlation, are uncertain, 32 subjects will be recruited to the
study.
12.2 STATISTICALMETHODS
For each of serum iron, maltol, maltol glucuronide, TSAT, TIBC, UBIC and transferrin,
concentrationdatawill belistedfor eachindividual subject,byformulation/condition. The
concentrationdata will be summarized, for each formulation /condition, at eachtime point
by using the following descriptive statistics: n (the number of subjects), arithmetic mean,
standarddeviation(SD),geometricmean,coefficientofvariation(CV),median,minimumand
maximum,anda90%confidenceinterval(CI)forthemean.
Concentration time courses of each component will be graphically displayed per subject.
Plots of the geometric mean and its 90% CI, by formulation, will be provided, overlaid, for
eachconditionseparately.
For serum iron, baseline corrected serum iron, maltol, maltol glucuronide, TSAT, TIBC, UIBC
and transferrin, PK parameters (C max, Tmax, AUClast, AUCinf,z, t½) will be calculated by non
compartmental analysis and listed by subject and by period. The parameters will be
summarized,foreachformulation/condition,byusingthefollowingdescriptivestatistics:n,
arithmeticmean,SD,geometricmean,CV,median,minimumandmaximum.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page60of66For each analyte, the within subject ratios between capsule and suspension of C max, AUClast
and AUC infwill be also be calculated and listed per subject, for each of the fed and fasted
conditions separately. These ratios will be summarized by n, geometric mean and a 90%
confidenceintervalforthemean.
Otherendpointsandsafetydatawillbelistedandsummarizedforeachformulation.
FulldetailswillbespecifiedintheAnalysisPlanpriortodatabaselock.
Allsecondaryendpointswillbesummarizedbyformulation/condition:
1. Treatment emergentAdverseEvents(TEAEs)
2. SeriousAdverseEvents(SAEs)
3. Treatment emergent Adverse Events leading to premature discontinuation of study
drug/PKassessments
4. Routineclinicallaboratorysafetybloodresults
5. Changesinvitalsigns
6. Concomitantmedications
12.2.1  SensitivityAnalyses
AnyplannedsensitivityanalyseswillbedocumentedintheSAPpriortodatabaselock.
12.2.2  ImputationofMissingData
Alldatawillbeusedaccordingtoavailability,withnoimputationformissingdata.
12.3 DEFINITIONOFPOPULATIONS
12.3.1  RandomizedPopulation
Allsubjectswhoarerandomized .
12.3.2  SafetyPopulation
All subjectswho have had at least one dose of study drug and one subsequent contact with
theInvestigatorwillbeanalyzedforsafety.
12.3.3  FullAnalysisSet
Allsubjectswhohavehadatleastonedoseofstudydrugandwhohaveatleastoneevaluable
postdose PK sample will be included in the FAS population. This population will be utilized
forthePKAnalysis.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page61of6613 ETHICALCONSIDERATIONS
TheSponsorandInvestigatormustcomplywiththisprotocol,allapplicablenationalandlocal
regulations including International Conference on Harmonization (ICH) and Good Clinical
Practice(GCP).
13.1 DECLARATIONOFHELSINKI
TheSponsorandtheInvestigatormustcomplywiththeprinciplessetforthbytheDeclaration
ofHelsinkidatedOctober2008.
13.2 INSTITUTIONALREVIEWBOARD/INDEPENDENTETHICSCOMMITTEE
The Investigator must ensure that the IRB/IEC has approved the protocol, the Information
SheetandConsentFormandanyotherrequiredstudydocumentspriortostartingthestudy.
The Sponsor must approve any changes to the Information Sheet and Consent Form before
submissiontotheIRB/IEC.
PriortoactivationofasiteandprovisionofIMP,theSponsormustreceivedocumentationto
demonstrate IRB/IECapprovalofthe requiredstudy documentsandmust have completeda
comprehensivesiteinitiationtrainingwiththeInvestigatorandsitestaff.
A progress reportmust be submitted to the IRB/IEC at least annually and more frequently if
requiredbytheIRB/IEC.
OncompletionorterminationofthestudytheInvestigatororSponsormustsubmitacloseout
lettertotheIRB/IEC(asrequired).AcopyoftheCSRsynopsiswillalsobesentinaccordance
withlocallaws.
13.3 SUBJECTINFORMATIONANDINFORMEDCONSENT
IRB/IECapproval of the writteninformation sheet and consent form must be obtained prior
to use. The Information Sheet will provide the subject with a complete and comprehensive
explanationofthestudyincludingthestudyrationale,theprocedures,thebenefitsandrisks,
thatparticipationisvoluntaryandthatthesubjectmaywithdrawfromthestudyatanytime
withoutanynegativeconsequences. Inaddition,aphysicianwilldiscussthisinformationwith
thesubjectwhowillbegivensufficienttimeandopportunitytohaveanyquestionsanswered
andtomakeadecisionofwhethertoparticipateinthestudy.
Written informed consent must be obtained from the subject in accordance with local
practice and regulations prior to any study assessment or test being conducted. Written
consentwillbeobtainedbysigninganddatingtheIRB/ECapprovedconsentforms.
Each consent form must also contain an authorization for the Sponsor and Investigators to
useanddiscloseProtectedHealthInformation(PHI)incompliancewithlocallaw.
Nostudyassessmentsorproceduresshouldbeconducteduntilwritteninformedconsenthas
beenprovided.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page62of66A copy of the information sheet and consent form signed and dated by the subject must be
given to the subject. The signed consent form(s) will be retained with the study records at
site. A description of the consent process must be documented in the subjects medical
record.
13.4 SUBJECTDATAPROTECTION
Prior to any study test being conducted, including Screening tests, the subject must provide
authorization as required by local law, eg. PHI. Subjects will not be identified by name (or
initials)intheeCRForanystudyreports.Datawillbeusedforresearchpurposesonly.Every
effort will be made to keep the subjects personal medical data confidential. All data will be
usedforresearchpurposesonly.
13.5 SUBJECTINSURANCE
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow
applicablelocalcompensationlaws.
13.6 CONFLICTOFINTEREST
Investigators should address any potential conflicts of interest (e.g. financial interest in the
Sponsor)withthesubjectbeforethesubjectmakesadecisiontoparticipateinthestudy.
13.7 REGISTRATIONOFSTUDYANDDISCLOSUREOFRESULTS
The Sponsor will register the study on all required registries (e.g. clinicaltrials.gov) and will
post study results regardless of outcome on publicly accessible websites in accordance with
theapplicablelawsandregulations.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page63of6614 STUDYMANAGEMENT
14.1 SOURCEDATA
TheInvestigatormustensurethatallsourcedocuments(i.e.,medicalrecords)andeCRFpages
arecompletedandmaintainedaccordingtothestudyprotocolandareavailableatthesite.
The Investigator should ensure clear records are maintained that demonstrate the integrity
of the data reported to the Sponsor via the eCRF. This includes all original records, certified
copies of clinical findings, observations or other activities necessary for reconstruction and
evaluation of the study. This includes, but is not limited to, Investigator signed/dated
laboratory reports and medical notes. Source data must not be changed without clear and
documentedrationale.Anychangesshouldbeconfirmedwiththeoriginator.Afullaudittrail
shouldalwaysbeavailabletoidentifythepersonmakingtheentryand/oramendments,the
originalentry/result,theamendmentandrationale.TheInvestigatormustensurethatsource
dataisalwaysattributable,legible,contemporaneous,originalandaccurate.
For this study, key data reported on eCRFs will be verified against source documents. The
eCRFwillnotactassourceexceptintheinstanceoflaboratorydatawhichwillbetransferred
directlytotheSponsor/designeeresponsibletoDataManagement.
14.2 QUALITYASSURANCE
During and/or after study completion, Sponsor quality assurance officers, IRB/IEC or
regulatory authorities may perform on site audits. The Investigator will be expected to
cooperate with any audit by providing assistance and access to all requested study related
records.
14.3 MONITORING
The Investigator must permit study related monitoring by providing direct access to source
dataandtothe subjects medicalrecords.TheMonitor(s)willvisittheInvestigatoratregular
intervalsduringthecourseofthestudyandaftercompletionofthestudyifneeded.
Duringthemonitoringvisits,eCRFs, source recordsandotherdocumentationrelating tothe
study will be made available for review. The Investigator will ensure any discrepancies or
omissionsareresolved.
Monitoring visits must be conducted according to the applicable ICH and GCP guidelines to
ensure protocol adherence, data quality, IMP accountability, compliance with
IRB/IEC/regulatory requirements and continued adequacy of the investigational site,
resourcesanditsfacilitiestoconductthestudy.
Frequency and scope of the monitoring visits will be defined in the Clinical Monitoring Plan
whichwillalsodefinetheextentofsourcedataverificationtobeconducted.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page64of6614.4 STUDYFUNDING
Shield TX (UK) Limited is the Sponsor and provides funding for the conduct of this study. All
financialdetailsareprovidedinclinicaltrialagreementsbetweentheinstitution,Investigator
andSponsor.
14.5 CONTRACTRESEARCHORGANIZATION(CRO)
A CRO (Medpace Inc.) will be contracted to be responsible for administrative aspects of the
studyincluding,butnotlimitedto,siteselectionandqualification,studyset up,siteinitiation,
monitoring, data management including clinical database and electronic CRF provisioning,
statistics and programming and study reporting. Vendors will also be contracted to cover
supportive services such as a central laboratory, bioanalysis of PK samples and IMP
production/labelling.
14.6 AMENDMENTSTOTHESTUDYPROTOCOL
The study will be conducted in compliance with this Protocol, as approved by all relevant
parties. Shouldanyamendmentstotheprotocolbedeemednecessary,thiswillberesolved
bymutualwrittenagreementbetweenthePrincipalInvestigatorandtheSponsor.
Any significant changes to the protocol shall be submitted to the IRB/IEC and Regulatory
Authoritiesandmustbeapprovedpriortoimplementationasrequiredbylocallaw.
However, the Sponsor may, at any time, amend this protocol to eliminate an apparent
immediatehazardtoasubject.Inthiscase,appropriatecommunicationsandnotificationsto
theIRB/IECandRegulatoryAuthoritieswilloccurasrequiredbylocallaw.
Amendments to the Information Sheet and Consent Form will be made if impacted by an
amendmentto thestudy protocolwhichwill alsobe submittedandapprovedtotheIRB/IEC
asrequiredbylocallaw.
14.7 STUDYSTOPPINGRULES
The Sponsormayterminate thisstudyat anytime. Inconsultation withthe Investigatoritis
normalproceduretoreviewtheemergingclinicalandsafetydata(section7.6). Asaresultof
thisreviewitmaybenecessarytostopthestudybeforeallsubjectshavecompletedthestudy.
Inthiscase,allsubjectswillbefollowed upforsafetyassessments.
The Sponsor will notify the IRB/IEC of discontinuation of the study and the reason for doing
so.
14.8 ENDOFSTUDY
Theendofstudyisthedateofthelastsubject,lastvisitforfinalcollectionofdata.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page65of6614.9 RETENTIONOFRECORDS
The Investigator must retain the informed consent documentation, disposition of the IMP,
hardcopyeCRFs,medicalrecordsandothersourcedataforatleast25yearsaftercompletion
or discontinuation of the trial or for at least 2 years after the granting of the last marketing
authorizationinthe EC(whenthereare no pendingorcontemplatedmarketingapplications
in the EC) or for at least 2 years after formal discontinuation of clinical development of the
investigationalproduct.Priortoproceedingwithdestructionofrecords,theInvestigatormust
notify the Sponsor in writing and receive written authorization from the Sponsor to destroy
studyrecords.
The Investigator must also notify the Sponsor of any changes in the archival arrangements
including, but not limited to, archival at an off site facility or transfer of ownership if the
Investigatorleavesthesite.
In addition, the Sponsor will retain copies / originals (as appropriate) of any study related
documentsintheTrialMasterFileuntilatleast2yearsafterthelastapprovalofamarketing
application in an ICH region, until there are no pending or contemplated marketing
applicationsinanICHregionoratleast2yearshaveelapsedsincetheformaldiscontinuation
ofclinicaldevelopmentoftheinvestigationalproduct.
14.10 SECURITYANDPUBLICATIONS
ThisstudyprotocolremainstheSponsorpropertyuntilthefinalfulfilmentofthecontractand
may only be passed on to registration authorities and license partners with the Sponsor /
Applicants approval. Thestudysitewill treatallknowledge aboutthestudyproductand/or
itsmanufacturerwithstrictestconfidentiality.
TheSponsorensuresthatsubstancesusedinthemanufactureoftheIMParegenerallyknown
inpharmaceuticalscienceandhavebeenreleasedbytheappropriatenationalauthoritiesfor
useinmedications,cosmeticsorfood.
Publication rights will be described in the Investigator contract. The study sitesagreement
is not required for using the study results for discussions with regulatory/governmental
authorities or for other purposes such as presentation at conferences, discussion with
potentiallicensingpartnersorspecialistgroups.
ProtocolST10 01104,Version 2.0,15Jul2020
CONFIDENTIAL Page66of6615 REFERENCES
BarrandMA,CallinghamBA.Evidenceforregulatorycontrolofironuptakefromferricmaltol
acrossthesmallintestineoftherat.BrJPharmacol1991a:102:408 14.
Barrand MA, Callingham BA, Dobbin P, Hider RC.Dissociation of a ferricmaltol complex and
its subsequent metabolism during absorption across the small intestine of the rat. Br J
Pharmacol1991b;102:723 9.
British Columbia Guidelines and Protocols. Iron deficiency investigation and management.
Effectivedate:15June2010.
BokemeyerB,KrummenerlA,MaaserC,HowaldtS, MroßM, MallardN. RandomizedOpen
Label Phase1Studyofthe PharmacokineticsofFerricMaltol inInflammatoryBowel Disease
PatientswithIronDeficiency.EurJDrugMetabPharmacokinet.2017Apr;42(2):229 238.
FoodEffect Bioavailability and Fed Bioequivalence Studies Guidance for Industry U.S.
Department of Health and Human Services Food and Drug Administration Center for Drug
EvaluationandResearch(CDER),December2002
Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anemia, and inflammatory bowel diseases. Gut
2004;53:11907.
Gasche C, Ahmad T, TulassayZ, BaumgartDC, Bokemeyer B, BüningC, Howaldt S, Stallmach
A; AEGIS Study Group. Ferric maltol is effective in correcting iron deficiency anemia in
patients with inflammatory bowel disease: results from a phase 3 clinical trial program.
InflammBowelDis.2015;21(3):579 88
Latestversionofthe Investigators BrochureforFerricMaltol(ST10 021,ST10).
MamulaP,PiccoliDA,PeckSN,MarkowitzJE,BaldassanoRN.Totaldoseintravenousinfusion
of iron dextran for iron deficiency anemia in children with inflammatory bowel disease. J
PediatrGastroenterolNutr2002;34:286 90.
SchmidtC,AhmadT,TulassayZ,BaumgartDC,BokemeyerB,HowaldtS,StallmachA, Büning
C; AEGIS Study Group.. Ferric maltol therapy for iron deficiency anemia in patients with
inflammatory bowel disease: longterm extension data from a Phase 3 study. Aliment
PharmacolTher.2016;44(3):259 70.
Thayu M, Mamula P. Treatment of iron deficiency anemia in pediatric inflammatory bowel
disease.CurrTreatOptionsGastroenterol2005;8:4117
Weiss G, Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease.
Haematologica2010;95:1758.
World Health Organization (WHO): Toxicological evaluation of certain food additives.
InternationalProgrammeonChemicalSafetyIPCS.WHOFoodAdditivesSeries1980;No.16:
123129.
World Health Organization(WHO): Evaluation of certain food additives. Sixty fifth report of
the Joint FAO / WHO Expert Committee on Food Additives. WHO Technical Report Series
2006;No.934:3641.